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clinical and cost-effectiveness of screening for lung
cancer using computed tomography (CT) to assist
policy making and to clarify research needs.
Data sources: Electronic databases and Internet
resources.
Review methods: A systematic review was
undertaken and selected studies were assessed using
the checklists and methods described in NHS Centre
for Reviews and Dissemination (CRD) Report 4.
Separate narrative summaries were performed for
clinical effectiveness and cost-effectiveness. Cost-
effectiveness analysis resulting in a cost per quality-
adjusted life-year was not feasible, therefore the main
elements of such an appraisal were summarised and
the key issues relating to the existing evidence base
were discussed.
Results: Twelve studies of CT screening for lung
cancer were identified, including two randomised
controlled trials (RCTs) and ten studies of screening
without comparator groups. The quality of reporting of
these studies was variable, but the overall quality was
adequate. The two RCTs were of short duration 
(1 year) and therefore there was currently no evidence
that screening improves survival or reduces mortality.
The proportion of people with abnormal CT findings
varied widely between studies (5–51%). The
prevalence of lung cancer detected was between 0.4%
and 3.2% (number need to screen to detect one lung
cancer = 31–249). Incidence rates of lung cancer were
lower (0.1–1% per year). Detection of stage I and
resectable tumours was high, 100% in some studies.
Adverse events, as a result of investigation or surgery,
or the screening process per se were poorly reported.
Incidental findings of other abnormalities requiring
medical follow-up were reported to be as high as 49%.
Six full economic evaluations of population CT
screening programmes for lung cancer were included in
the review. The magnitude of cost-effectiveness ratios
reported varied widely. None was set in the UK and
generalisation was complicated by wide variation in the
data used in different countries and a paucity of UK
data for comparison. All six made the fundamental
assumption that screening with CT for lung cancer
reduced mortality. At the current time, there is no
evidence to support that assumption. In the absence of
evidence of health gains from screening for lung cancer,
in terms of either quantity or quality of life, and faced
with a range of uncertainties, from the frequency of
abnormal screening findings within a population to the
natural history of screening detected lung cancers, it is
not feasible at the current time to develop accurately
and meaningfully an economic argument for CT
screening for lung cancer in the UK. For subgroups, in
particular certain occupational groups, there is
evidence of increased risk of lung cancer, but the role
of screening has not been demonstrated by the current
studies.
Conclusions: The accepted National Screening
Committee criteria are not currently met, with no
RCTs, no evidence to support clinical effectiveness and
no evidence of cost-effectiveness. RCTs are needed to
examine the effect of CT screening on mortality, either
with whole-population screening or for particular
subgroups; to determine the rate of positive screening
and detected lung cancers. Research is also needed to
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of screening-detected lung cancers, particularly small,
well-differentiated adenocarcinomas; as well as the
impacts on quality of life. Increased collection is needed
of UK health service data regarding resource use and
safety data for lung cancer management and services.
Research is also needed into the feasibility and logistics
of tracing people who have in the past worked in
industry where there was exposure to lung
carcinogens.
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ContentsGlossary
Baseline screening Sometimes also referred
to as prevalence screening, describes the first
time a population is screened.
Incidence screening All subsequent CT
examinations conducted at a known time
interval. New or altered nodules will be reported.
Any detected tumours will have developed since
the previous CT examination (i.e. new disease).
Lead-time bias Screen-detected patients are
accorded extended survival times solely because
cancer was detected earlier owing to screening,
although death occurred at the same time as
would have happened without screening (i.e.
the intervention yields no benefit).
Length bias Screening introduces a bias in
relation to expected survival by detecting more
patients with less aggressive disease (who have
longer survival) and fewer of those with more
aggressive disease.
Non-calcified nodule Used in screening
studies to denote any lesion in the lung in
which malignancy cannot be ruled out and for
which the study protocol indicates that further
follow-up is required.
Over-diagnosis bias Small, slow-growing
lesions are detected by screening for
intervention that would never become
symptomatic within a patient’s lifetime in the
absence of screening.
Pack-years The number of years that the
individual has smoked an average of one pack
of 20 cigarettes per day.
Screening test validity Assessed by
considering the following four components of
the test: 
• sensitivity: proportion of individuals with the
disease who are correctly identified by the
test
• specificity: proportion of individuals without
the disease who are correctly identified by
the test
• positive predictive value: proportion of
individuals with a positive test result who
have the disease
• negative predictive value: proportion of
individuals with a negative test result who do
not have the disease.
Another aspect of assessment of the validity of
the test is precision: this assesses the
reproducibility of the results of the test.
Spiral (helical) computed tomography
Rather than doing one slice at a time as in
standard CT, the X-ray tube rotates around the
patient at the same time as the patient is
moved through the scanner. This reduces the
time taken to scan.
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.Glossary and list of abbreviations
viii
List of abbreviations
AE adverse event
ALARA as low as reasonably achievable
BL baseline screening
CEA cost-effectiveness analysis
CHART continuous hyperfractionated
accelerated radiotherapy
COPD chronic obstructive pulmonary
disease
CRD Centre for Reviews and
Dissemination
CT computed tomography
CUA cost–utility analysis
CXR chest X-ray
DARE Database of Abstracts of Reviews
of Effectiveness
ELCAP Early Lung Cancer Assessment
Project
FU follow-up
HRCT high-resolution computed
tomography
HSE Health and Safety Executive
IARC International Agency for
Research in Cancer
ICER incremental cost-effectiveness
ratio
INAHTA International Network of
Agencies for Health Technology
Assessment
INC incidence screening
LDCT low-dose computed tomography
LYG life-years  gained
NA not applicable
NCI National Cancer Institute
NCN non-calcified nodule
NHS EED NHS Economic Evaluation
Database
NICE National Institute for Health and
Clinical Excellence
NNS number needed to screen
NPV negative predictive value
NR not reported
NSC National Screening Committee
NSCLC non-small cell lung cancer
PAH polycyclic aromatic hydrocarbon
PET positron emission tomography
PPV positive predictive value
QALY quality-adjusted life-year
QoL quality of life
RCT randomised controlled trial
RR relative risk
SCLC small cell lung cancer
SEER Surveillance, Epidemiology and
End Results
SF-12 Short Form 12
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Health Technology Assessment 2006; Vol. 10: No. 3
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Background
Screening for lung cancer has been the subject of
debate for the past three decades. This has largely
stemmed from the results of chest X-ray screening
studies where improvements in survival were
obtained but without reductions in disease-specific,
or total, mortality. The debate raises two issues:
the design of studies to evaluate screening for
lung cancer, in particular the choice of
comparator; and the potential role of over-
diagnosis of well-differentiated, slow-growing
tumours that would not have led to symptoms or
death in the lifetime of the affected patient.
Lung cancer is the leading cause of death from
cancer in the UK, killing approximately 34,000
people per year. By the time symptoms develop,
the tumour is often at an advanced stage and the
prognosis is bleak. Treatment at a less advanced
stage of disease with surgical resection has been
shown to substantially reduce mortality. Screening
would be attractive if it could detect
presymptomatic lung cancer at a stage when
surgical intervention is feasible.
Objectives
The aim of this review is to examine the clinical
and cost-effectiveness of screening for lung cancer
using computed tomography (CT) to assist policy
making and to clarify research needs.
Methods
Search strategy
Fifteen electronic databases and Internet 
resources were searched from 1994 until
December 2004/January 2005. In addition,
bibliographies of the retrieved articles were
searched and the register of projects held by the
International Network of Agencies for HTA
(INAHTA) was also checked.
Inclusion/exclusion criteria
Studies were included where screening for lung
cancer was the principal theme of the paper. The
initial search was for randomised trials in which
survival in a group receiving CT screening was
compared with a group not screened, but because
of the lack of such studies, no restriction was
placed on study type. Studies were reviewed by two
authors independently. 
Data extraction
Data extraction included details of the screening
protocol, follow-up, diagnosis and participants.
Information was sought about test characteristics,
including sensitivity and specificity. The checklists
and methods described in NHS Centre for
Reviews and Dissemination (CRD) Report 4 were
used for the quality assessment of studies.
Analysis
Separate narrative summaries were performed for
the clinical effectiveness and cost-effectiveness.
Cost-effectiveness analysis resulting in a cost per
quality-adjusted life-year was not feasible,
therefore the main elements of such an appraisal
were summarised and the key issues relating to the
existing evidence base were discussed.
Results
Summary of clinical effectiveness
In total, 12 studies of CT screening for lung
cancer were identified, including two randomised
controlled trials (RCTs) and ten studies of
screening without comparator groups. The quality
of reporting of these studies was variable, but the
overall quality was adequate. The two RCTs were
of short duration (1 year) and therefore there was
currently no evidence that screening improves
survival or reduces mortality. The proportion of
people with abnormal CT findings varied widely
between studies (5–51%). The prevalence of lung
cancer detected was between 0.4 and 3.2%
(number need to screen to detect one lung cancer
= 31–249). Incidence rates of lung cancer were
lower (0.1–1% per year). Detection of stage I and
resectable tumours was high, 100% in some
studies. Adverse events, as a result of investigation
or surgery, or the screening process per se were
poorly reported. Incidental findings of other
abnormalities requiring medical follow-up were
reported to be as high as 49%.
Executive summaryx
Summary of cost-effectiveness
Six full economic evaluations of population CT
screening programmes for lung cancer were
included in the review. The magnitude of cost-
effectiveness ratios reported vary widely. None was
set in the UK and generalisation was complicated
by wide variation in the data used in different
countries and a paucity of UK data for
comparison. All six made the fundamental
assumption that screening with CT for lung cancer
reduced mortality. At the current time, there is no
evidence to support that assumption.
Economic appraisal
In the absence of evidence of health gains from
screening for lung cancer, in terms of either
quantity or quality of life, and faced with a range
of uncertainties, from the frequency of abnormal
screening findings within a population to the
natural history of screening detected lung cancers,
it is not feasible at the current time to develop
accurately and meaningfully an economic
argument for CT screening for lung cancer in the
UK. For subgroups, in particular certain
occupational groups, there is evidence of increased
risk of lung cancer, but the role of screening has
not been demonstrated by the current studies.
Conclusions
The accepted National Screening Committee
criteria are not currently met, with no RCTs, no
evidence to support clinical effectiveness and no
evidence of cost-effectiveness.
Recommendations for research
In terms of what information is needed to assist
decision-making about CT screening for lung
cancer, the following research priorities were
identified.
  RCT evidence is needed about the effect of CT
screening on mortality, either with whole-
population screening or for particular
subgroups. One such trial is underway in the
USA, recruiting 50,000 participants, and is due
to end in 2009, although final follow-up will not
complete until around 2014.
  UK data about the rate of positive screening
with CT and detected lung cancers could be
obtained from an RCT or a cohort study. Even
relatively small-scale studies would provide
valuable information when trying to assess the
generalisability of RCT data currently being
conducted elsewhere.
  There is a need to understand better the
natural history and epidemiology of screening-
detected lung cancers, particularly small, well-
differentiated adenocarcinomas. This could be
met, in part, by lung cancer screening RCTs or
cohort studies, but a review of existing
published epidemiological and pathological
data, along with primary analysis of UK lung
cancer epidemiology, would usefully inform
current understanding.
  Information about the quality of life impact 
of CT screening, acceptability of screening, 
and uptake and retention rates in the UK 
would be valuable in any future assessment 
of the cost-effectiveness of screening in 
the UK.
  Increased collection is needed of UK health
service data regarding resource use and safety
data for lung cancer management and 
services.
  Research is needed into the feasibility and
logistics of tracing people who have in the past
worked in industry where there was exposure to
lung carcinogens.
Executive summaryT
his review was commissioned by the UK HTA
Programme on behalf of the National
Screening Committee (NSC). The aim of this
review is to examine the clinical effectiveness of
screening for lung cancer using computed
tomography (CT), taking into account the effect
on mortality, detection of early disease and the
impact on quality of life. An economic appraisal is
also provided. One stimulus for the review has
been publicity about the use of whole body CT
screening. This review will not consider the
effectiveness of screening for conditions other
than lung cancer, but will report on incidental
disease findings. A separate review will consider
the case for screening for heart disease and, if
appropriate, the economic case for dual screening
will be addressed.
Health Technology Assessment 2006; Vol. 10: No. 3
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Chapter 1
Aim of the reviewIntroduction
Although smoking rates have fallen, and
improvements in treatment have occurred, lung
cancer remains the leading cause of death from
cancer in the UK. The principal hope for curative
treatment remains surgical resection, which
requires tumours to be recognised early, before
local invasion or remote spread of disease.1
Improvements in CT technology, in particular the
increased rapidity of imaging facilitated by spiral
CT, make the detection of smaller lung
abnormalities and mass screening feasible, at least
in theory. There is currently no mass-screening
programme for lung cancer in the UK.
This technology appraisal was undertaken to
inform the NSC discussions about the feasibility of
screening for lung cancer using CT. Following an
introduction to lung cancer and issues
surrounding screening in this chapter, the
evidence regarding the clinical effectiveness
(Chapter 3) and cost-effectiveness (Chapter 4) is
reported. An economic appraisal is provided
(Chapter 5). Compatibility with the NSC criteria
for a screening test is then examined (Chapter 6).
Finally, the weaknesses of the research evidence,
recommendations for future research and the
implications for clinical practice are discussed
(Chapter 7).
Lung cancer: the burden of disease
Lung cancer is the leading cause of death from
cancer in the UK. Over the past two decades there
has been a reduction in incidence of lung cancer
in men and a slowing in the rate of increase
among women, related largely to the fall in
smoking rates and reduction in tar content in
cigarettes. Despite this, approximately 34,000
people die annually from lung cancer across the
UK: 20,000 men and 14,000 women. Overall
survival after diagnosis is poor (less than 10% at
5 years) with little improvement in the rates over
the past 10 years despite advances in
chemotherapy regimens for lung cancer.2
The classification of lung cancer divides the
disease into three main types: non-small cell lung
cancer (NSCLC), small cell lung cancer (SCLC)
and mesothelioma. NSCLC accounts for about
83% of all lung cancers.2 Overall survival is poor
among patients with NSCLC, but surgical resection
offers a potential cure for some. Survival varies
substantially with clinical stage of tumour at
diagnosis, with a 60–70% 5-year survival among
those with stage IA disease but less than 10% for
those with stage III disease or worse. Pathological
staging, based on a tissue biopsy and therefore
generally considered to be more accurate, shows a
similar pattern.2,3 More than 50% of people with
lung cancer present with tumours at stage III or
later.2,4
Histologically, the most common type of NSCLC
presenting clinically is squamous cell carcinoma.
In the UK, it accounts for 35–45% of all lung
cancers, with adenocarcinoma and large cell
accounting for 15% and 10%, respectively.
Adenocarcinoma is the least strongly associated
with smoking and generally occurs in periphery of
the lungs.2
SCLC is typically aggressive, generally presenting
with invasive disease and surgery is rarely, if ever,
indicated. Mesothelioma is a rare cancer of the
pleural lining of the lung accounting for less than
1% of all lung cancer.4 It is strongly associated
with asbestos exposure. Like SCLC, the outlook
after diagnosis is bleak with little potential for
curative therapy at present. Given current
treatments, it is only people with NSCLC who
have a potential to benefit from a screening
programme that would enable disease to be
identified before local or distant spread.
The risk of developing lung cancer varies across
the population and a number of risk factors can
be identified. The incidence of lung cancer rises
with age and is rare below the age of 40 years. The
highest incidence rate occurs among over 70-year-
olds.2
In the UK, lung cancer remains more common in
men than women, despite the incidence falling in
men in recent years (Figure 1).5
The biggest single risk factor for lung cancer is
smoking, with 85–90% of all people who present
Health Technology Assessment 2006; Vol. 10: No. 3
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Chapter 2
Backgroundwith lung cancer having a history of smoking.6
Both the number of cigarettes smoked per day
and the duration of smoking are among the
important factors that correlate with risk of lung
cancer. The risk of lung cancer among lifelong
heavy smokers is up to 50 times that of non-
smokers of similar age.6 Close temporal links can
be seen between the fall over the past two decades
in smoking frequency and cigarette tar yields, and
male lung cancer mortality. Former smokers
experience a substantial decline in risk of lung
cancer as the time since last cigarette increases: 
a 34% reduction in the first 10 years, and reducing
to close to the risk for a lifelong non-smoker by 
30 years. Stopping smoking even up to the age of
60 years has been shown to reduce substantially
the risk of developing lung cancer.7,8
Smoking is by no means the only risk factor for
lung cancer and increased risks of lung cancer
have been reported in association with a variety of
occupational exposures. The estimated risk
associated with various occupations and key
reviews are summarised below and in Appendix 1.
Lung cancer and occupation
The occupational contribution to lung cancer is
underestimated and tends to be appreciated only
where a well-recognised potential cause is
identified, notably asbestos exposure. From a
number of studies of specific workforce
populations the International Agency for Research
in Cancer (IARC) has identified 16 specific
occupations, exposures or processes that they class
as having ‘sufficient evidence’ to say that they
cause lung cancer (IARC evidence grade 1)9,10
(Table 1, with fuller review in Appendix 1).
The two main causes of occupational lung cancer
are asbestos and silica, but there remains
considerable discussion as to whether lung cancer
can develop in the absence of associated lung
fibrosis. For instance, the estimated relative risk
(RR) for workers exposed to silica varies between
no increased risk and a relative risk of
approximately 1.3. However, patients with silicosis
show a greater increased risk (estimated RR
around 2.3). A similar situation exists with respect
to asbestos. The relative risk of lung cancer in
patients with asbestosis is around six-fold higher
than in the non-exposed population, whereas
asbestos exposure itself carries a smaller risk (RR
varying between 1.2 and 2.0 in selected studies,
but not increased in others).
In some occupations, carcinogenic exposures may
be multiple (e.g. chemical workers). In addition,
many workforces are increasingly exposed to diesel
fumes, which are currently recognised to be a
‘probable’ (IARC class 2A) carcinogen. For
workforces where diesel is the only exposure, the
estimated relative risk for lung cancer lies between
1.3 and 1.5. A range of other occupations is
associated with an increased risk for lung cancer,
although the relative risks are smaller than those
seen with asbestos (see Appendix 1). It may,
therefore, be more important to consider
occupation rather than specific exposures when
determining whether a workforce may be
considered for CT screening for lung cancer. It is
also important to note that the interpretation of
many of the studies contributing to the IARC
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FIGURE 1 Lung cancer incidence and mortality rates in the UK, 1975–2002. (Reproduced from Cancer Research UK.5)evidence base are complicated by heavy 
co-exposure to cigarette smoke.
Certain workforce groups appear to be at greater
risk of lung cancer than the general population
and some may, therefore, merit special
consideration when identifying a potential
population for screening. When assessing the risk
of developing lung cancer in a workforce,
consideration needs to be given to the size of the
workforce (at one site or in a specific group of
industries) and to the change in exposure pattern
over time, bearing in mind the latency of
development of lung cancer and changes in work
processes aimed at reducing specific exposures.
For instance, while arsenic is recognised as a lung
carcinogen, very few workers in the UK are now
occupationally exposed and exposure levels in
those exposed are very low. Consequently, current
risk to those workers is essentially that of the
normal population. In at-risk workers who are
older and who experienced worse working
conditions early in their working lives, risk will be
higher whatever the current exposure. The
workforce most exposed to asbestos is now ageing
and often no longer in the employment of the
industry that resulted in their exposure. As a result
there are substantial logistical difficulties
associated with trying to identify at-risk
occupational groups for the purposes of a
screening programme.
The increased risk of lung cancer associated with
certain occupations and exposures, particularly
asbestos, may warrant consideration of the
feasibility of a screening programme for workers
or ex-workers. A case would have to be made on
an occupation-by-occupation basis, with evidence
not only of their risk of lung cancer, but also of
the feasibility of running an effective screening
programme in that population.
Despite reductions in smoking and a fall in the
incidence of lung cancer, at least among males,
lung cancer remains a serious public health issue,
affecting large numbers of people and with a bleak
prognosis when presenting after symptoms
develop. Treatment of stage I and II disease with
surgical resection has been shown to reduce
mortality substantially. Screening for lung cancer
is an attractive proposal, particularly since
symptomatic disease is strongly associated with
more advanced and inoperable cancer.
Current service provision
There is no screening service for lung cancer in
the UK. The NSC reviewed the topic in March
2004 and concluded that the policy not to offer
screening should continue.
Imaging technology for lung
cancer screening
The chest radiograph (chest X-ray) remains the
most commonly used imaging technique in the
investigation of respiratory disease, but it is not a
sensitive test for pulmonary nodules, with an
estimated 50% of nodules measuring 6–10 mm
being missed owing to superimposition of the
chest wall, heart and mediastinal structures.11
The past 30 years have brought revolutionary
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TABLE 1 Agents with ‘sufficient evidence’ (IARC grade 1) to be classed as occupational lung carcinogens9
Agent Main industry/use
Arsenic (inorganic) and arsenic compounds Glass, metals, pesticides
Asbestos Insulation, filter material, textiles
Beryllium and beryllium compounds Aerospace industry/metals
Bis chloromethyl ether Chemical intermediate/by-product
Cadmium and cadmium compounds Dye/pigment manufacture
Chloromethyl methyl ether (technical grade) Chemical intermediate/by-product
Chromium (VI) compounds Metal plating, dye/pigment manufacture
Coal-tar pitches Building materials, electrodes
Coal tars Fuel
Crystalline silica Stone cutting, mining, glass and paper industries
Mustard gas War gas
Nickel compounds Metallurgy, alloys, catalyst
Radon decay products Underground uranium and hard rock mining
Soots Pigments
Talc-containing asbestiform fibres Paper, paints
Tobacco smoke (personal and environmental) Alldevelopments in imaging techniques, including
the development of CT. 
The first generation of CT systems had an X-ray
tube and a single row of detectors that were
positioned on opposite sides of a ring that rotated
around the patient lying on a mobile table. During
each rotation of the ring, the X-ray tube produced
a narrow beam of X-rays that passed through the
patient to the row of detectors, acquiring a single
axial image with a slice thickness of 1 cm. The
table then moved the patient a set distance
through the system, acquiring the next axial
image. A physical link was required between the 
X-ray tube and a power supply and after each
rotation the ring had to stop and rotate in the
opposite direction. The first generation of CT
systems was of limited value in the investigation of
chest disease, as total examination times were long
and the images were prone to artefact due to
movement with respiration. In addition, small
lesions could be missed if they were present
between the thick axial slices.12
The incorporation of slip-ring technology into
scanners in the late 1980s resulted in the
development of spiral (helical) systems. The slip
ring is an electromechanical device that allows the
transmission of power and electrical signals from a
stationary to a rotating structure. This allowed the
X-ray tube to rotate continuously, while the table
carrying the patient advanced. Data could be
acquired rapidly with slices as thin as 1 mm and
with image acquisition times as short as one
breath-hold of 15–20 seconds.
Further advances with multiple rows of detectors
have led to multislice CT. These systems have four
to 64 detector rows that acquire multiple image
slices during each rotation of the X-ray tube.
Image acquisition times are, therefore, faster with
less movement artefact as a result.12 The type of
system being used in studies for CT screening for
lung cancer is generally spiral CT, but multislice
CT systems could also be used.
The advances in CT mean greater sensitivity than
plain chest X-ray in the detection of pulmonary
nodules. CT has the potential to detect pulmonary
nodules as small as 1–2 mm owing to the high
contrast between nodules and aerated lung. A study
assessing the sensitivity of spiral CT for pulmonary
nodules, using surgical exploration and histological
analysis as the gold standard, showed the sensitivity
of spiral CT to be much higher than previous
reports of standard sequential CT with a sensitivity
of 100% for intrapulmonary nodules larger than
10 mm, 95% in nodules larger than 5 mm and 66%
in nodules less than or equal to 5 mm.11
However, the newer generation scanners are
expensive, with greater capital costs and increased
running and maintenance costs for replacement
components. Sophisticated data storage and
management systems are required and, because of
the volume of data produced, there are increased
interpretation and reporting times. In the UK in
2002, a typical spiral scanner could be expect to
have one tube replaced per year, at a cost of
around £25,000.
In screening, the balance between image quality
and radiation dose is particularly important and
every effort should be made to minimise the
radiation dose. There are differences between
countries in how CT parameters are set, and
different countries have different priorities in this
balance between image quality and safety. It has
been estimated that the lifetime risk of developing
cancer attributable to all diagnostic X-rays is
0.6–1.8%. In the UK this equates to up to 700
cancers per year.13 It is imperative to obtain a
radiological diagnosis with the lowest radiation
dose that is reasonably achievable (the ALARA
principle).14 Compared to chest X-ray, CT results
in exposure to higher radiation doses. At present,
the National Radiation Protection Board states
that the average effective dose from a standard-
dose spiral CT of the thorax is 8 millisieverts
(mSv), whereas chest X-ray is around 0.1 mSv and
mammography 0.4 mSv. The average background
radiation dose in the UK is 2.2 mSv. The risk of a
fatal cancer of any type is estimated to be 1 in
2500 for standard-dose CT of the thorax.15 CT of
the thorax imparts the highest radiation dose to
the lungs and breast tissue and as a result the
radiation dose is higher in women.
To minimise the radiation dose, low-dose
schedules have been developed. It is possible to
reduce the dose by decreasing the tube current
from the standard 140–400 mA to 20–140 mA.
The resulting effective radiation dose equivalent is
much lower, 0.3–0.6 mSv.16 Studies comparing
spiral CT of the thorax obtained at standard tube
current with those obtained at reduced tube
current showed no reduction in the detection of
pulmonary nodules in patients with known or
suspected pulmonary nodules.11,17 Most studies of
CT screening for lung cancer incorporate the use
of low-dose spiral CT regimens.
Therefore, CT technology now affords us with a
mechanism to image the thorax rapidly and with
Background
6substantially more detail than using chest X-ray.
However, these advances come at an increased cost
and radiation dose.
CT-detected abnormalities
As discussed already, CT can detect very small
abnormalities within the lung fields. Discrete
pulmonary nodules are the most commonly
reported abnormality that may be suggestive of
malignancy, but abnormal scarring and ground-
glass opacities are also recognised as potentially
malignant changes. Unfortunately, CT
abnormalities are not specific for malignancy and
some series report more than 90% of CT nodules
to be benign.18 Radiologists report a number of
features that assist in differentiating between
benign and malignant lesions. Demonstration of
fat within the nodule is a reliable feature of benign
lesions, but is rarely seen. Benign patterns of
calcification support the diagnosis of non-
malignant lesions such as hamartomas and
granulomas (associated with tuberculosis,
histoplasmosis and other granulomatous diseases),
but the evidence base is limited.1 Nodules
suspicious of malignancy are often referred to as
non-calcified nodules (NCNs) in the screening
literature. The term NCN refers to the fact that
the nodule cannot be excluded from being
malignant based on the pattern of
calcification.11,19
Size is also important in determining the
likelihood that an NCN is malignant, and large
lesions are more likely to be malignant than small
lesions. Analysis from one of the CT screening
studies reports that, of 378 positive baseline
screening CTs identifying NCNs of less than
5 mm, none proved to be malignant on further
investigation. In contrast, 3.3% of those 5–9 mm
and more than 50% of those greater than 9 mm
were malignant.18
Screening programme
requirements
Screening is not simply about the technology used,
but the whole programme, including call and
recall of the screening target population using
primary care records to identify smokers,
investigation of the positive screenees and all
associated services. In terms of equipment and
staff, access to a spiral CT and experienced CT
personnel is essential, along with specialist
radiologists to interpret the images. CT systems
are generally available across the NHS
(approximately seven per million population).20
A current investment programme aims to replace
all CT systems over 11 years old in the next
3 years. Despite recent investment, most are
already heavily committed to a service workload.
In addition, staffing in the existing radiology
service, in particular with radiologists and
radiographers, is already stretched. For some
regions of the UK, distance to travel to a CT
system is long and access may be an important
issue in promoting screening uptake. Mobile
screening units have been described and could
potentially improve access.21 Support services,
including a mechanism to call and recall
participants, personnel to counsel participants in
making informed choices about screening, and the
facilities and staff to deliver the required follow-up
in a timely fashion, are all crucial to the screening
programme. Follow-up is complex and includes
detailed imaging plus, where necessary, interval
CT examination for signs of growth. The principal
aim of follow-up is to minimise the number of
people being exposed to tissue biopsy and the
associated risks (10% of people undergoing
percutaneous transthoracic needle biopsy require a
chest drain and 0.04% die as a result of biopsy
complications).1 The screening programme would
aim to identify more people who could be offered
surgical resection. The effect would be to increase
demand on surgical services, but potentially to
reduce the number requiring radiotherapy or
chemotherapy.4 Screening will also identify cancers
at an advanced stage and non-surgical oncology
services will be necessary to deliver the care these
individuals need.
The attitudes of the public towards screening will
be important in ensuring good participation in
any screening programme and adherence to a
screening protocol. The authors are not aware of
any published studies evaluating patient attitudes
to lung cancer screening in the UK. A small survey
(62 participants) conducted by the Roy Castle
Lung Cancer Foundation asked delegates at a
conference (delegates were largely patients with
lung cancer and their relatives) about their views
on screening: 92% responded that the UK should
take part in a study of CT screening for lung
cancer. When offered the option to abandon
further research into screening and just start a
screening programme, 87% responded ‘yes’
(Baird J, Director of Patient Care, Roy Castle Lung
Foundation: personal communication; 18 March
2005). In the USA, a survey of 172 smokers and
former smokers found that 62% expressed an
interest in CT screening for lung cancer.22 There
Health Technology Assessment 2006; Vol. 10: No. 3
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CT screening in the USA.
Other current issues
Screening for lung cancer has been the subject of
debate for the past three decades. Several
systematic reviews of screening for lung cancer
using chest X-ray, alone or in combination with
sputum, have concluded that there is insufficient
evidence of benefit in terms of reduction in
disease-specific mortality.23–25 However, there has
been much criticism in the literature of both the
methods and interpretation of these studies.
First, several of the studies did not use placebo as
the comparator and instead compared intensive
screening with less frequent screening, or chest 
X-ray alone with chest X-ray plus sputum. These
studies could not, therefore, assess whether
screening was better than no screening. Second,
the studies, despite consistently demonstrating
improved survival, did not demonstrate
improvements in disease-specific or total mortality.
Without evidence that overall mortality is reduced,
improvements in survival time may be subject to
three types of bias: over-diagnosis, length bias and
lead-time bias. 
  over-diagnosis bias: small, slow-growing lesions
are detected by screening for intervention that
would never become symptomatic within a
patient’s lifetime in the absence of screening
  length bias: screening introduces a bias in
relation to expected survival by detecting more
patients with less aggressive disease (who have
longer survival) and fewer of those with more
aggressive disease, because the duration of
asymptomatic disease is longer in less
aggressive tumours.
  lead-time bias: screening-detected patients are
accorded extended survival times solely because
cancer was detected earlier owing to screening,
although death occurred at the same time as
would have happened without screening (i.e.
the intervention yields no benefit).
Conclusion
CT is more sensitive than chest X-ray in detecting
small pulmonary nodules but that raises additional
issues for a screening programme in terms of both
the clinical significance of these very small
abnormalities and the potentially large number of
false-positive screening CT examinations.
Investigation, therefore, becomes a trade-off
between the probability of the nodule being
malignant and the risks associated with further
investigation. Diagnostic tests are not without
hazards and the challenge of obtaining tissue
diagnosis is greater in very small nodules. There
has been no consensus to date about how best to
manage these small, screening-detected nodules.
Given the lack of evidence of effectiveness for
screening with chest X-ray, this review will only
consider the effectiveness of CT screening in
comparison to current practice; that is, no
screening programme.
The main issues when considering screening for
lung cancer using CT therefore include:
  Should there be screening with CT for lung
cancer at all? Does it meet the UK NSC criteria
for a screening test?
  If there is screening, should it be universal or
selective? 
  Which CT schedule should be used as a
screening test?
  Which CT screening protocol should be used?
Within a screening programme, the frequency
of screening, call and recall processes, and
management of those who test positive will all
be important in determining clinical and cost-
effectiveness.
  What cut-off should be used for defining a
positive screening test? Small lung nodules are
not an infrequent finding on CT, and not all are
malignant. There is debate about how to best
investigate and manage people with such
findings.
  What is the gold-standard test if someone
screens positive? A tissue diagnosis plus
imaging is generally required to diagnose and
stage lung cancer. Biopsy has associated risks,
and there has been debate about the option to
follow up small nodules with imaging to
determine growth rate before committing to
biopsy.
  What are the consequences if screening is
positive for lung cancer but at an inoperable
stage? 
  Is universal or targeted screening for lung
cancer cost-effective?
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Literature search
Preliminary searches showed that very few
randomised controlled trials (RCTs) had been
conducted to evaluate screening for lung cancer
using CT. The search was not, therefore, restricted
by study design. All primary studies evaluating CT
screening for lung cancer were included.
Systematic reviews were also sought and assessed
for quality. The conclusions of the systematic
reviews are reported under a separate section in
the discussion. A sensitive search strategy
(described in full in Appendices 2 and 3),
including the keywords of lung cancer, CT
examination and mass screening, was constructed
to search MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews, Cochrane
CENTRAL Register of Controlled Clinical Trials,
NHS Economic Evaluation Database (NHS EED),
HTA Database, Database of Abstracts of Reviews of
Effectiveness (DARE), Bandolier, Health
Management Information Consortium, American
Society of Clinical Oncology, Research Findings
Register, National Horizon Scanning Centre,
Science Citation Index, Web of Science
Proceedings and National Research Register. The
register of projects held by the International
Networks of Agencies for Health Technology
Assessment (INAHTA) was also checked. For
completeness, the search strategy was not
restricted by language; where reports in a
language other than English were identified, they
were noted but translations were not sought. The
searches were restricted to cover from 1994 to the
present and the search was last updated on 
5 January 2005 (unless otherwise stated in
Appendix 3). The bibliographies of included
studies were also searched, but authors of included
studies were not contacted for further information.
Selection of papers
The sensitive search identified a large number of
potential titles. Each title and abstract was
reviewed by two of the authors (CB and RDV) to
assess the relevance to this review. Two categories
of titles were included for data extraction: (1) for
inclusion in the clinical effectiveness review and
(2) for inclusion in the cost-effectiveness review.
The inclusion and exclusion criteria were:
  screening for lung cancer was the principal
theme of the paper
  primary research (RCT, cohort or case–control,
economic analysis) or systematic review 
  CT screening compared with no screening (or, if
a study included a comparison group that were
screened using an alternative screening method,
then only data from the CT screening arm of
the study included).
There was no important disagreement between the
two reviewers that was not resolved by discussion.
Studies evaluating the use of methods for
screening for lung cancer other than CT were not
included, nor were those that evaluated the use of
CT for other conditions (e.g. whole-body
screening or screening for coronary artery
calcification). Studies evaluating the use of CT for
diagnostic or staging purposes in lung cancer were
also excluded.
Relevant papers were retrieved and reviewed by
two authors independently. Data extraction
included details of the screening protocol, 
follow-up, diagnosis and participants. Information
was sought about test characteristics, including
sensitivity and specificity. The checklists and
methods described in Centre for Reviewers 
and Dissemination (CRD) Report 4 were used 
for the quality assessment of studies.26 A summary
of the data extraction for each included 
study is provided in Appendix 4. Papers meeting
the criteria for the review of cost-effectiveness
studies are dealt with separately in 
Chapter 5.
Outcomes of interest
This review was not simply interested in the
effectiveness of CT in detecting lung cancer, but in
the effectiveness in the context of a mass
population-screening programme. The principal
outcome of interest, as discussed in Chapter 2, was
the effect of the screening programme on disease-
specific mortality (i.e. lung cancer mortality) and
on total mortality. While studies with no
comparator group could provide information
about the screening process, the natural history of
the detected nodules and survival, only RCTs
could provide information about the effect of
screening on mortality.
Health Technology Assessment 2006; Vol. 10: No. 3
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Chapter 3
Evidence of clinical effectivenessAn improvement in disease-specific mortality
requires not only that CT examination is 
effective, but also that the entire screening
programme and management of those with
positive screening tests is effective. In a population
at increased risk of mortality from other causes
(i.e. smoking and cardiovascular disease), total
mortality is more important in judging
effectiveness of screening.
Additional outcomes of interest in assessing the
effectiveness of CT screening programmes 
were:
  What proportion of people were found to 
have abnormal CT examinations at 
screening?
  What proportion of those people had lung
cancer?
  What proportion were stage I and resectable
tumours?
  What was the survival among those with lung
cancer detected by screening?
Outcomes were also sought that are likely to have
a service impact; that is follow-up requirements,
quality of life issues and adverse events.
Summary of included studies
Included studies
A total of 12 studies of CT screening for lung
cancer was identified for inclusion in the review of
clinical effectiveness. Several of these studies have
been described in multiple publications. Table 2
summarises the 12 studies, indicating the main
reference used for each study and any additional
publications. Two RCTs were identified, but one of
these used a comparator group that received chest
X-ray screening.27,28 Therefore, only the
experience from the CT-screened arm was
included in the main analysis. A further nine
studies without comparator groups were reported
in the review of clinical effectiveness. In addition,
one study describing a comparator group initially,
but then failing to report details of this group any
further, was included for the CT intervention arm
details.29 In all ten of these studies, participants
who agreed to take part in the study all received
CT screening and were followed up over time to
assess outcomes. The limitation of this design is
discussed in Chapter 2 (section ‘Other current
issues’, p. 8).
Two components of the screening programmes 
are reported throughout this section: 
baseline screening and incidence screening. These
two terms are defined below.
Baseline screening, sometimes also referred to as
prevalence screening, describes the first time a
population is screened for lung cancer. In this
situation, there will be a mixture of people with
tumours that have begun to grow recently and
tumours that have been developing for some time
but have not yet caused symptoms. In addition,
this may be the first time that the lungs have been
imaged in an individual and, therefore,
radiologists have nothing for comparison when
interpreting the CT examination, with the effect of
making it more difficult to determine the
malignant potential of the NCN. Change in a
lesion is a strong marker of malignant potential.1
Incidence screening refers to all subsequent CT
examinations conducted at a known time interval.
New or altered NCNs will be reported. Any
detected tumours will have developed since the
previous CT examination (i.e. new disease) and
will, in theory, either be at an early stage or, if at
an advanced stage, then will be aggressive, fast
growing tumours. In having at least one previous
CT examination for comparison, radiologists are
often able to exclude an abnormality as
representing possible malignancy on the basis of
no change in size during the intervening period.
Unfortunately, there were no data from the UK. In
total, 25,749 people have participated in baseline,
one-off CT screening and, in all, 54,342 CT
examinations for the purposes of screening for
lung cancer have been reported. Five of the 12
studies were conducted in the USA and a further
three in Japan. The remaining four took place in
Germany, Italy, Ireland and Finland (Table 2).
All the studies included involved CT screening
with five of the studies only reporting the findings
after one round of CT screening. In Kaneko,37
participants also received a chest X-ray and
sputum examination. Swensen46 included sputum
examination. ELCAP included a baseline chest X-
ray.33 Gohagan randomised participants to be
screened with chest X-ray or CT, but as chest X-ray
has not been demonstrated to be an effective
screening method for lung cancer the results of
this arm of the study are reported in the table only
and the comparison is not discussed in detail.28
Sone reported identifying false-negative CT
examinations on the basis of sputum, but did not
detail in the methods whether sputum samples
were routinely obtained in all screened
participants.29
Evidence of clinical effectiveness
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RScreening participants
Although all the studies clearly described their
inclusion and exclusion criteria, they did not
provide an evidence base for why certain cut-offs
were selected. All studies based entry criteria for
screening on three participant characteristics: age,
smoking history and fitness for surgery. 
Age
It is known from cancer registries that the
incidence of lung cancer increases with age, so it is
of little surprise to find lower age restrictions on
screening. The youngest study participants were
40 years old (Table 2). 
Smoking
Two of the studies in Japan included smokers and
non-smokers.29,51 The remaining studies restricted
their screened populations to those with a history
of at least 10 ‘pack years’ (i.e. an average of one
pack of 20 cigarettes per day for 10 years). ‘Pack
years’ are widely used to summarise smoking
history, but have limitations including translating
from other forms of tobacco use, interpreting
intensity of smoking and considering threshold
exposure levels. The two RCTs limited the study
populations to those who had a smoking history of
more than 30-pack years.27,28 Time since smoking
cessation was incorporated into three of the
studies by restricting screening to those who were
smokers within the 10 years before
recruitment.28,46,52
In the studies, participants were interviewed about
smoking history after volunteering to participate.
A screening programme in the UK could be
mediated via GPs who could restrict invitation to
those patients with a recorded history of smoking.
Until recently, the recording of smoking data in
primary care computer records has been
variable.56 However, the new GP contract includes
incentives to record smoking status in all patients
aged 15–75 years as well as additional contractual
requirements to record smoking status in people
with asthma, COPD, diabetes or cardiovascular
disease.57
Fitness for surgery
Most studies reported some degree of assessment
of fitness for surgery before proceeding to
screening. There are three principal reasons for
this: fitness to hold breath for the duration of the
CT data acquisition, fitness for diagnostic
procedures and fitness for surgical resection.
While radical radiotherapy is an option for those
not fit for surgical resection, adequate lung
function is still a prerequisite for treatment. In
addition, the survival gain from radical
radiotherapy [including continuous
hyperfractionated accelerated radiotherapy
(CHART)] is nowhere near as good as surgical
resection in stage I or stage II tumours (17% 
5-year survival with radiotherapy versus 60–70%
with surgery).1
None of the studies reported the proportion of
people failing to meet the entry criteria based on
fitness. Given the population at risk of lung
cancer, co-morbidities may be significant, with
other tumours, cardiovascular disease and COPD
having the greatest impact on fitness for surgical
resection. In a male population screened for
abdominal aortic aneurysm in the north-west of
Scotland and similar to potential lung cancer
screenees in terms of age and smoking history,
only 0.6% (62/9657) of the volunteers were
considered not to be fit for elective surgical
aneurysm repair by the GPs at initial assessment.58
However, fitness for aortic aneurysm repair may be
very different to fitness among smokers for
pneumonectomy. It is, therefore, difficult to
anticipate what proportion of the potential
screening population in the UK would meet 
the criteria for screening based on fitness for
surgery.
Subgroup at high risk of lung cancer
In addition to the population criteria identified
above, a number of the studies included additional
subgroups identified by the researchers to be at a
potentially increased risk of lung cancer. These
included the following.
COPD
COPD is strongly associated with heavy smoking
and, as a result, lung cancer. One RCT27 selected
some of its participants based on the presence of
obstructive airways disease confirmed by
pulmonary function tests. Those with COPD were
required to have sufficient lung capacity (and
adequate general health) to undergo surgical
resection, if required. In addition to having
COPD, this group was further defined to be at
high risk of lung cancer by having atypical 
sputum cytology.
Occupational exposure
Numerous types of workplace exposure have 
been associated with an increased risk of lung
cancer and were summarised in Chapter 2.
Workers exposed to asbestos, silica (especially
patients with associated fibrosis), radiation and
chrome (e.g. electroplaters, chemical workers)
have been reported as having double the risk of
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populations. Polycyclic aromatic hydrocarbon
(PAH) exposure is high in coke-oven workers and
there are, historically, high relative risks
associated with asphalt workers and chimney
sweeps (RR 17.5 and 16.2, respectively). These
are important occupational risk factors for lung
cancer in the UK setting. 
The association between asbestos exposure and
intrathoracic cancers has been recognised for
many years. The Health and Safety Executive
(HSE) estimates that around 6000 occupational
cancers (all forms) occur each year, of which 
3500 are due to asbestos (essentially all thoracic
malignancies). Of these asbestos-related
malignancies, in 2003, 1900 were mesotheliomas
and most of the remaining 1600 were NSCLC.59
One study of CT screening included only workers
who had been exposed to asbestos.53 A further
three of the studies included a subgroup (2–14%
of the total study population) within the study who
had a history of asbestos exposure.30,40,52 None of
these papers quantified the extent of asbestos
exposure.
The only other study dealing with occupational
exposure was by Miller and colleagues in the
USA.55 They report a screening programme in a
workforce employed in the nuclear fuel industry
with exposure to a number of risk factors
including radiation, asbestos and beryllium. 
No other occupational exposure groups were
identified that have participated in studies for CT
screening for lung cancer.
The screening process
CT technology 
Ten of the studies reported using some form of
spiral CT system and two used mobile systems that
were not otherwise specified.21,29,55 Effective
radiation dose was poorly reported, but two
studies estimated exposure to be 0.6 mSv for men
and 1.1 mSv for women.40,50 All but one of the
studies reported using low-dose protocols and,
where reported, the CT parameters included tube
voltages of 120–140 kVp, tube currents of
25–60 mA and pitch of 2:1. Huuskonen and 
co-author reported using standard dose CT with
tube currents of 125–200 mA.53 The duration of
CT data acquisition was not well reported, but
varied between single and two breath-holds and 
15 to 40 seconds.
Definition of a positive screening CT
For the most part, the definition of a positively
screened image was based on the detection of an
NCN (Table 3) In Diederich40 and Swensen,46 any
image with one or more nodules of any size was
treated as positive. Studies conducted by
Pastorino50 and Huuskonen53 also used these
criteria, but specified that any nodule must be
greater than 5 mm to be significant. The RCT
conducted by Gohagan28 defined positive images
as those with nodules greater than 3 mm in size
and in addition included spiculated NCNs less
than or equal to 3 mm. Gohagan also included
focal ground-glass opacification and
endobronchial lesions. Henschke,30 Garg27 and
MacRedmond52 all specified that CT examinations
with one to six nodules of any size were classed as
positives. The presence of more than six nodules
was considered to represent diffuse disease.
Further, MacRedmond also included ground-glass
opacities and mediastinal masses. The study
conducted by Nawa51 included images with fewer
than six nodules that were greater than 7 mm in
size as positive.
Two Japanese studies, Kaneko37 and Sone,29 used
a subjective rating system where radiologists
determined the likelihood of cancer without
specifying what features of the CT examination
made cancer more likely. 
Miller55 did not specify the criteria used for
defining a positive examination. Those images
that were found to be indeterminate or suspicious
were said to be positive.
Follow-up of positive screening
examinations
Most studies used similar guidelines when
following up positive screening CT examinations:
small nodules were followed up with imaging to
detect growth, and larger nodules and nodules
demonstrating growth were biopsied or resected.
Henschke30 and MacRedmond,52 for example,
followed up with high-resolution CT (HRCT) for
nodules 5 mm or smaller, performed at 3-, 6-, 12-
and 24-month intervals for growth. HRCT was
restricted to one or two slices to minimise
radiation dose. For larger nodules immediate
biopsy was considered. Miller55 also followed up
positive CT examinations by rescanning with an
HRCT technique.
Garg27 and Diederich40 used repeat low-dose 
CT (LDCT) screens to detect growth in small
lesions. In Garg27 nodules larger than 10 mm 
were further evaluated with contrast-enhanced 
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Pastorino50 followed up nodules 5 mm or larger
with HRCT and contrast enhancement in selected
cases. Nodules 7 mm or larger on HRCT were
then followed by PET scans. Further, nodules were
biopsied if there was positive enhancement or a
positive PET scan.
Quality of included studies
There were three main issues of study quality that
had implications for the interpretation of results
for the UK setting (details given in data extraction
summaries, Appendix 4). First, none of the studies
reported information about the representativeness
of their samples. All samples were obtained on a
volunteer basis. It is difficult to interpret how well
these volunteers represented the general
population to whom screening may be offered.
Second, the duration of follow-up was limited in
most studies, with few presenting data beyond 2
years. Given the outcomes of interest, survival and
disease-specific mortality, this short duration is a
problem. It was further complicated by the high
attrition rates in the studies of longer duration,
where compliance with the screening programme
of annual CT scans appears to be poor. Finally, the
Evidence of clinical effectiveness
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TABLE 3 Definition of positive CT screening examinations
Study Definition Size No. of  Other features
nodules
Garg, 200227 NCN any 1–6 None
Gohagan, 200428 NCN >3 mm (any for Unspecified Ground-glass 
spiculated NCN) opacities +
endobronchial
lesions
ELCAP , 200130 NCN Any 1–6 Ground-glass
opacities
Diederich, 200440 NCN Any 1 or more None
Swensen, 200346 NCN Any 1 or more None
Pastorino, 200350 NCN >5 mm 1 or more None
Nawa, 200251 NCN >7 mm 1 to 6 None
MacRedmond, 200452 NCN any 1 to 6 Ground-glass
opacities +
mediastinal
lesions
Miller, 200455 Unspecified Any 1 or more None
Sone, 200129 (A) Examination unsatisfactory
(B) Normal
(C) Lung abnormality of little clinical 
importance
(D) Non-cancerous lung lesion
(Ed) Non-cancerous but suspicious 
lung lesion
(E) Suspicion of lung cancer
(F) Small lung nodule (<3 mm in diameter)
(Ed, E and F seem to be considered suspicious)
Kaneko, 200237 (A) Inadequate image Any 1 or more None
(B) Normal
(C) Scar lesion caused by a previous 
inflammatory episode
(D) Benign tumour or an active inflammatory 
disease
(E) Suspected lung cancer
Huuskonen, 200253 NCN >5 mm 1 or more Nonelack of comparator groups in most of the studies
means that it was not possible to determine the
impact of screening on lung cancer and total
mortality rates in comparison with no screening.
Other general points about the quality of the
studies relate largely to the quality of reporting in
the papers. Many studies have reported annual
interim results. In one study in particular it was not
possible to reconcile either the details of the
participants (i.e. age of included participants) or
the number screened.29,44,45 Where this occurred,
the data extractors made a judgement as to which
report was the most complete and this was used. In
several studies the reporting of withdrawals from
the screening programme was poor and similarly
the following of screen-positive patients through
their follow-up was not always complete or accurate.
The details of the quality issues are provided in the
data extraction summaries in Appendix 4
Outcomes of screening
The main outcomes of interest are summarised in
Table 2 and in the data extraction summaries in
Appendix 4.
Positive CT examinations
As outlined above, the definition of a positive CT
examination has not been universally agreed. It is
not unsurprising, therefore, that there is some
variation in the rate of positive CT examinations.
What is more surprising is the extent of the range,
from 5.1%29 to 51%46, at baseline. Seven studies
report incidence CT examinations. The incidence
rate for positive CT was substantially lower than
baseline (3–11.5%). From the 12 studies, 4146
positive CT examinations were reported from
baseline screening and a further 1677 from
incidence screening in the seven studies in which
more than one screening round had occurred.
Two of the three studies restricting the definition
of positive to only those with NCNs greater than
at least 5 mm in diameter50,51 reported baseline
screening to be positive in 5.9–7% of the
population. In the third study,53 baseline positive
reporting was high (18.4%). Sone,29 asking the
radiologists to identify lesions suspicious of cancer
or indeterminate, produced the lowest positive
screening results (5.1%), but Kaneko,37 using
similar definitions, found 11.5% of baseline CT
examinations to be positive.
Compared with chest X-ray, CT screening
identified more people with positive screening
results. The one RCT study28 comparing CT
screening with chest X-ray identified almost
double the number of people with NCNs at
baseline by CT compared with chest X-ray (20.5%
versus 9.8%). At baseline, ELCAP identified 23.3%
of people as having positive CT examinations.
Chest X-rays in the same study participants only
detected NCNs in 6.8% (and more than half of
these were considered not to be nodules on CT).30
In Kaneko,37 CT and chest X-rays were carried out
in each study participant and approximately ten
times more nodules were detected by CT than by
chest X-rays.
Investigations and follow-up
Management of positive screening CT varied by
study, but generally involved either follow-up by
further CT to observe for change in size, or if very
suspicious of cancer (because of size, other
features or growth) then biopsy was
recommended. In most of the studies the study
coordinators managed the screening part of the
programme and recommendations for further
clinical management of the results were made to
the attending physicians. Almost all of those with
positive CT screening were recommended for
follow-up with at least one further CT. Not all
recommendations were followed, because of
physician or participant choice. Biopsies were
carried out in 3–27% of positive screenees. The
studies report only a small number of cases where
a biopsy was recommended but not carried out, or
biopsies were undertaken when not recommended
by the study protocol. After an incidence CT,
6–35% of positive screenees were biopsied. Table 2
shows the range of biopsy rates obtained in the
screened population. Insufficient information was
reported to identify what proportion had CT-
guided biopsy or bronchoscopy with biopsy or
bronchoalveolar lavage to obtain tissue for
diagnostic purposes. 
Detection of lung cancer
Prevalence and incidence
A total of 215 patients with lung cancers was
diagnosed as a result of 25,749 baseline screening
CT examinations. The highest prevalence of lung
cancer was reported in the five studies from the
USA (0.6–3.2%). Prevalence rates in the studies
from Europe and Japan were generally lower
(<1.0%), except for the German study with a
reported prevalence of 2.1%.40 In the seven
studies with incidence data, a further 87 cancers
were identified. Incidence rates varied from
0.07%51 to 1%.50 Five studies29,30,37,40,46 reported
more than 1 year of annual CT screening data, but
in all the compliance with follow-up was poor
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positive screening CT examinations went on to
receive a diagnosis of lung cancer confirmed, in
most, by histology. Among the four studies with
the lowest rates of positive screening CT
examinations,29,37,50,51 Pastorino had the highest
positive predictive value for CT screening.50
Most lung cancers detected by baseline screening
were NSCLC (206/215, 96%). Adenocarcinoma was
the major histological type reported in nine of the
12 studies (range 33–94%). At incidence screening,
SCLC still accounted for a small proportion of the
total (2/87, 2.3%).
The numbers of interval cancers were reported in
four studies using annual screening protocols.
Reporting was not consistent, and the term
‘interval cancer’ included not only new lesions that
developed for the first time between CT
examinations, but also for tumours that were, in
retrospect, visible on the previous screening CT
examination. The one study with CT examinations
twice per year did not report any interval
tumours.37
Stage
Between 53 and 100% of prevalent tumours were
identified as stage I disease (with the exception of
the Huuskonen study,53 where only one of the five
tumours identified was stage 1). For incidence
tumours, 71–100% (excluding Diederich, where
only three incidence tumours were detected40)
were reported to be stage I disease. Three studies
did not report stage adequately. Only three studies
reported a higher percentage of stage I tumours at
incidence scanning than at prevalence scanning,
although detection of stage I disease was high in
both screening settings.27,52,55
Resectability
Where reported, the resectability of tumours found
by screening was high, more than 80% in most
studies (Table 2). Not all participants agreed to
surgery. The resection rates reported in the
screening studies are substantially higher than
current clinical experience in the UK.4,60 The CT
screening studies did not clearly report what types
of surgical resection were conducted. In the UK,
the current National Institute for Health and
Clinical Excellence (NICE) guidelines indicate
that, where possible, lobectomy is the surgical
procedure of choice when curative resection is the
intention.1 There will be situations where this is
not feasible for clinical reasons and more limited
resection may be appropriate. However, the NICE
guidelines were not constructed to provide
evidence for the best management of very small
lung cancers detected by mass-population CT
screening, and the most effective surgical option
for such tumours is not known.
Quality of life
None of the studies reported any data about
quality of life in the screening participants. There
were data about the impact of a positive test result
(or negative result) on quality of life. Similarly,
there were no data about the quality of life in
those undergoing further investigation or surgery.
Several did note the high positive rate from the
initial screening CT and speculated on the impact
that this, along with the subsequent follow-up
regimen, may have on screening participants in
terms of anxiety pending definitive diagnosis.
A subgroup of participants in the large Prostate,
Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO) in the USA, using chest X-ray to
screen for lung cancer, have completed health-
related quality of life questionnaires [Short term
12 (SF-12) plus cancer-specific distress questions]
at baseline and during the first year of follow-up.
This study reports a significant increase in cancer-
specific anxiety in the short term among those
who receive abnormal screening results. Once
abnormal tests were known to be false positives,
anxiety fell back to that of the group with normal
screening results. Ongoing participation with the
screening programme was, however, influenced by
previous false-positive results (93.7% adherence
versus 78.7%).61
Test accuracy results
One of the difficulties in estimating test accuracy
is the absence of a gold standard. Therefore, true
cases of lung cancer were determined by tissue
confirmation at biopsy or surgery or, in a few
cases, on the basis of detailed CT enhanced by
contrast medium (where tissue sample was not
possible). Truly negative results could only be
determined by the absence of presentation with
disease over a period of time (or at subsequent
screening). Interval tumours were reported in
three of the studies and some authors commented
on whether, in retrospect, these lesions had been
visible at screening but missed. This was not
generally reported in detail. Only one study29
reported sensitivity and specificity results for CT
screening. Where available data allowed, the
sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) for the
screening test were estimated (Table 4). Studies
that did not report follow-up of the screened
population for at least 12 months were excluded
Evidence of clinical effectiveness
18Health Technology Assessment 2006; Vol. 10: No. 3
19
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
TABLE 4 CT test accuracy results
Study FU >12 months Interval  CT wrongly  Detected by  Accuracy
tumours reported negative another test
(in retrospect)
Gohagan, 200428 Insufficient FU
Garg, 200227 Insufficient FU
ELCAP , 2001: Yes 2 4 None Sens: 27/33 = 81.8%
Baseline31 Spec: 763/969 = 78.7%
PPV: 27/233 = 11.5%
NPV: 763/767 = 99.5%
ELCAP , 2001:  Not reported 
year 1+230 by year
Insufficient 
follow-up
Kaneko, 200237 Yes None  None reported 1 (sputum) PPV: 13/186 = 7.0%
reported
Diederich, 2004: Yes 5 2 (of the 5 interval  NA Sens: 20/22 = 90.9%
overall40 tumours) Spec: 2111/2530 = 83.4%
PPV: 20/439 = 4.6%
NPV: 2111/2113 = 99.9%
Sone, 2001:  Yes None  17 1 (sputum) Sens: 22/40 =55%
Baseline29 reported Spec: 5186/5443 = 95.3%
PPV: 22/279 =7.9%
NPV: 5186/5204 = 99.7%
Sone, 2001:  Yes None  3 2 (administrative Sens: 25/30 = 83.3%
year 129 reported error) Spec: 4247/4395 = 96.6%
PPV: 25/173 = 14.5%
NPV:4247/4252 = 99.9%
Swensen, 2003: Yes 2 4 (but information  2 (sputum) PPV: 35/1118 = 3.1%
overall46 not given by year) Unable to estimate as
details by screening round
not presented
Pastorino, 2003: Yes None  6 (all visible but  NA Sens: 11/17 = 64.7%
baseline50 reported correctly classified  Spec: 968/1018 = 95.1%
as negative) PPV: 11/61 = 18%
NPV: 968/974 = 99.4%
Pastorino, 2003:  Insufficient FU
year 150
Nawa, 2002:  Yes Not  3 None Sens: 36/39 = 92.3%
baseline51 reported Spec: 7412/7917 = 93.6%
PPV: 36/541 = 6.7%
NPV: 7412/7415 = 99.9%
Nawa, 2002: Yes None  Not reported None PPV: 4/148 = 2.7%
incidence51 reported
MacRedmond, Insufficient  FU
200452
Huuskonen, 200253 Insufficient 
information
Miller, 200455 Insufficient 
information
Sens, sensitivity; Spec, specificity.from these estimates as insufficient time had
elapsed for missed lung cancers to have presented.
Where interval cancers were not described, or no
discussion was made of reviewing the previous
year’s CT examinations, only PPV was estimated.
Reflecting the high false-positive rate from CT
screening, the PPV was universally poor (<20%),
regardless of the protocol adopted for defining a
positive CT. Where positive screening CT was
based on subjective radiologist assessment of risk
of malignancy, the PPV tended to be slightly
higher (7–14% versus 2–5%). The predictive value
of a negative CT was high (>95% where it could be
estimated). Despite the high NPV, people with
abnormalities were missed. Two studies reported
detecting positive baseline CT examinations when
reviewing the previous annual CT (i.e. missed
NCNs): Swensen found 25% of the first year’s CT
examinations to be positive in retrospect,46 and
Diederich found 5% to be positive in retrospect.40
The most rigorously reported review of annual CT
examinations was by Sone and colleagues.29 When
reviewing the CT examinations of those with
cancer, they identified a high proportion that
could, in retrospect, be seen in the baseline CT
screening. This appeared to relate to radiologist
experience and was not repeated in the subsequent
year’s results. In the remaining studies, where it
was possible to make some estimate of false
negatives, the sensitivity was around 80–90%. CT
screening for lung cancer performed well in terms
of specificity and a negative CT examination result
was highly predictive of no lung cancer. It should
be noted that not all interval tumours are evidence
of false-negative screening CT, but may also
include new disease that has truly developed in the
interval (i.e. is not visible in retrospect on the
baseline CT). In addition, some could be seen in
retrospect on the original CT, but were correctly
classified as negative at that time because they were
very small (only an issue for the studies using a
bottom cut-off for size). This was true of the
Pastorino study, where six tumours, identified in
year 2 CT examinations, were visible but very small
in year 1; all were considered resectable and were
stage IA disease at the year 2 CT examination.50
Survival
The information available regarding survival is
summarised in Table 2. Only one study37 reported
5-year survival, with 76.2% of the people with
cancer detected at baseline CT (n =14) surviving
for 5 years and 64.9% of the incident CT-detected
cancers surviving for 5 years (n = 22). In ELCAP,
after 2 years of follow-up for tumours diagnosed at
the baseline screening CT, none had died
(n = 27).30 Sone reports two deaths among the 50
people diagnosed and surgically treated in the
first 2 years of their screening programme (follow-
up period estimated to be approximately
2–3 years, but not reported).29 In one of the
occupation screening group studies, survival was
particularly poor, with no patients surviving for
more than 2 years (n =5).53 Follow-up in the
remaining studies was short and the duration of
individuals’ follow-up was not adequately reported
in these studies to allow comment on survival.
Within the screened populations, death due to
other causes, in particular cardiovascular disease,
was not infrequent. 
Mortality rates
None of the studies reported total or disease-
specific mortality rates. In the most part, follow-up
was too short. Where several years of screening
had occurred, follow-up was limited to those still
participating in the screening programme. The
two randomised trials were effectively pilot studies
and did not continue long enough to determine
effect on mortality. None of the other studies had
comparator groups; therefore, change in disease-
specific mortality between those screened with CT
and those not screened could not be assessed. 
Other outcomes
Impact on smoking behaviour
A small subgroup of 134 smokers at one of the
centres participating in the ELCAP was surveyed
about smoking attitudes and behaviour after
baseline CT screening.36 Quitting was associated
with younger age, perception of risk and fear of
cancer, and having had an abnormal CT
examination. Long-term follow-up of smoking
behaviour was not available. Seventy-four per cent
said that it increased their motivation to quit
smoking, and 23% reported having quit. A further
26% reported a reduction in smoking.
Unfortunately, the timing of the follow-up
interviews in relation to the CT examination was
not reported. Similarly, a subset of the Swensen
study was randomised to different smoking
cessation interventions in conjunction with CT
screening.47 Swensen and co-authors reported that
higher attempt rates of smoking cessation were
achieved with the provision of Internet-based
resources. The rates of cessation are similar to
those reported with other types of smoking
cessation programmes such as nicotine
replacement. None of the studies reported
whether any participants felt ‘exempt’ after
receiving a normal CT examination and therefore
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smoking. Positive CT examinations were associated
with a higher motivation to quit.36
At-risk subgroups
Age
Three of the studies29,37,40 presented results by age
band, and separated baseline and incidence
screening (Table 5). Kaneko showed a gradient in
both positive screening CT examinations and lung
cancers with increasing age.37 At incidence
screening, this trend was not as apparent.
Diederich did not report a gradient with age, but
included very small numbers of participants in the
older age bands.40 All were consistent in
identifying no cases of lung cancers in those aged
less than 45 years. Similarly, in the studies with
higher minimum age restrictions, the proportion
with detected cancers tended to be higher.
Smoking
Two of the Japanese studies29,51 included smokers
and non-smokers in the screening programme.
Only one of these,29 however, reported results in
sufficient detail to allow comparisons between
smokers and non-smokers. Of the 5483 screening
participants, 54% were people who had never
smoked. Although 44% of the study population
were female, among the women less than 6%
smoked, whereas 93% of the men were smokers.
The proportion of people at baseline screening
with lung cancer who were never smokers was
0.44%, similar to that of smokers (0.40%). In the
non-smokers, the lung cancer was statistically
significantly more likely to be a well-differentiated
adenocarcinoma (90% of tumours in non-smokers
versus 48% in smokers).
COPD
Of the 55 COPD participants with atypical sputum
in the US study by Garg, 22 (40%) had NCNs on
CT screening and underwent further
investigation.27 In two patients NSCLCs were
diagnosed (3.6% of COPD participants).
Completed follow-up of those with smaller nodules
has not as yet been reported. In comparison, the
37 smokers with no history of COPD had eight
(22%) NCNs detected by CT with only one
NSCLC on biopsy (2.7%). 
Unfortunately, there was no follow-up information
on the management or survival of those with
COPD and lung cancer. Survival among people
with COPD is generally reported to be poor, with
age, continued smoking and forced expiratory
volume in 1 second (FEV1) being strong
predictors.62 Screening for lung cancer may not
achieve the same benefits because of mortality
from other causes. Among those with moderate
respiratory failure and advanced airflow limitation
[arterial oxygen tension (PaO2) 7.4–8.7 kPa and
FEV1/forced vital capacity (FVC)
postbronchodilator <70%] 3-year survival has
been reported to be around 66%.63
Asbestos
Huuskonen and co-authors reported a workforce-
screening programme for 602 participants with
asbestos-related disease identified in an earlier
study of asbestos-exposed workers in Finland.53 Of
the workers screened, 65 (11%) required follow-up
of some sort after the screening CT and five were
found to have lung cancer (plus one who was
diagnosed late after symptoms and a false-
negative screening test) (1% lung cancer
prevalence). Only one underwent resection and all
died within 21 months of diagnosis.
Miller and colleagues also studied workforce
screening, but this time in a nuclear fuel industry
workforce in the USA.55 Thirty-two per cent of
these workers had positive CT examinations on
screening, but only 0.6% were diagnosed with lung
cancer.
The low prevalence of cancer in the workforce
screening studies may reflect the age of the
screened population, restricted to working age.
The two studies do not report the age of the
screened population in any detail. Neither
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TABLE 5 Outcome trends by age group
Study (prevalence screening)
Kaneko, 200237 Diederich, 200440 Sone, 200029
Age (years) CT +ve (%) Lung cancer (%) CT +ve (%) Lung cancer (%) Lung cancer (%)
40–49 8.9 0 16.4 0 0.8
50–59 11.1 0.38 19 0.96 0.6
60–69 11.6 1.43 11.6 4.2 0.6
70–79 15.8 1.49 3.1 0 1.5workforce study reported the extent of exposure to
potential carcinogens among the workforce.
The other four studies with subpopulations
exposed to asbestos did not report separate data
for their outcomes.
Adverse events
General
Adverse events, as a result of any part of the
screening programme, were poorly reported. Only
Gohagan reported fully adverse events potentially
associated with investigation for positive screening
CT.64 Six patients experienced adverse events (a
total of eight complications: three pneumothorax,
two infections/fever requiring antibiotics, one
atelectasis, one stroke and one acute respiratory
failure). In addition, one person died 5 months
after screening, but this was not attributed to
screening. Kaneko reported two deaths in the
6 months after surgery from infection in the
absence of tumour recurrence.38
Surgical deaths and morbidity were not reported
in these studies. NICE guidelines for lung cancer
report the mortality from all thoracic surgery with
curative intent for NSCLC to be 3.5% (range
1–7.6%), with a further 30% experiencing
morbidity.1
Radiation exposure
None of the studies provided information about
the risk of cancer induced by radiation exposure
as a result of screening. The follow-up period was
too short in most, if not all, of the studies. As none
of the RCT studies reported more than
preliminary findings, again no comment could be
made about incidence rates of tumours in those
exposed to radiation versus those not exposed.
The International Commission on Radiological
Protection predicts that CT examination with
LDCT, using the type of regimens described in the
screening studies (~1 mSv estimated effective
radiation dose), would induce five cancers per
100,000 CT examinations.11 Additional radiological
exposure occurs with each repeat annual CT and
any additional imaging investigations.
Incidental findings
Reporting of incidental findings (i.e. other than
lung cancer) was variable and related to the
specified screening protocol. One study37
restricted the radiologists to only examining the
lung fields for pathology, while the others allowed
full chest images.30,40 Two studies reported in
detail the findings other than NCNs. Fourteen per
cent46 and 49.2%52 had findings other than NCNs
that merited further investigation. Swensen
reported 17 other cancers, 35 adrenal masses and
33 renal masses among the 817 screened
individuals.46 In MacRedmond, COPD (29%) and
coronary artery calcification (14.3%) were the most
commonly reported findings.52 Kaneko, who only
reported other malignancies, identified 14
additional malignancies of the chest wall and
mediastinum among the 7891 screening CT
examinations conducted.37 Garg reported one
patient with metastatic laryngeal tumour and one
with multiple granulomatous disease.27
Service implications of screening
Although a number of the studies recognised the
substantial costs to the health service in terms of
screening per se and the follow-up of large
numbers of positive screening CT examinations,
none reported the costs beyond the cost of
conducting the screening CT (including the
examination itself, staff and reporting costs). The
costs reported varied from US$50 to 200 per CT
and tended to be lower in Japan than in the other
study countries. No discussion of quality control
criteria or mechanisms, administration
requirements, or impact on oncology or surgical
services was reported.
In all of the studies with greater than 1 year of
screening experience, the number of participants
in the screening programme fell dramatically with
each successive year (Table 2). Only one study had
reasonable participant retention,46 with less than
5% loss after 2 years. At 2 years, ELCAP had lost
65% of study participants.30 Diederich
experienced similar losses at 2 years (33%) and
reported on only 24 people who had undergone 
5 years of annual screening.40 Losses included
people who had died, developed lung cancer and
failed to return for annual screening on time
(although some may have been screened at
intervals of greater than 1 year, but these were
reported separately, or excluded, by most authors).
Summary of other systematic
reviews
Several reviews of this topic have been published.
Twenty-five reviews were identified from
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were considered to be systematic reviews and are
summarised in Table 6. One only considered chest
X-ray screening.65 The other two concluded, as
have the present authors, that while there is
evidence of a higher detection rate than with chest
X-ray and small, resectable lesions are found, it is
not yet possible to assess what effect this will have
on mortality.24,25
Summary
In the absence of RCT evidence to examine the
relative effectiveness of CT screening on disease-
specific mortality and total mortality, other study
evidence was considered. None of the 12 studies
reported disease-specific or total mortality. Only
one study reported survival data. It is not,
therefore, possible at present to assess whether CT
screening for lung cancer is clinically effective.
There is evidence that CT detects a greater
number of NCNs and other suspicious chest
abnormalities than chest X-ray. There is also
evidence that smaller NCNs are detected by CT
than by chest X-ray.
Substantial variation was seen between studies in
terms of the proportion of screenees with positive
CT examinations and the rate of cancer detected.
The difference in results is to some extent
explained by the different definitions of a positive
CT examination. Despite this, where similar
definitions were used, variation still existed. The
difference in rates of detection of lung cancer
between studies highlights the need for caution in
generalising findings from other countries to the
UK setting.
Baseline screening identified more stage I disease
than the literature reports for series of lung cancer
in the absence of screening. Incidence screening
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TABLE 6 Summary of systematic reviews of screening for lung cancer
Study Search Search  Inclusion Quality Meta- Main  conclusions
methods comprehensive criteria  assessment analysis 
described? stated described done
Bepler, 200325 Yes Yes Yes Yes No Evidence for lung cancer screening
by CT showed that it detects ‘earlier
stage’ and smaller lung cancers with
greater frequency than other
screening modalities. Best suited to
populations with low probability of
benign pulmonary abnormalities. In
such a population, the highest PPV
for lung cancer would be in people
above 60 years of age. Until
mortality studies are completed,
low-dose spiral CT screening should
be considered an investigative tool
rather than standard care
Manser, 200165 Yes Yes Yes Yes Yes Current evidence did not support
screening for lung cancer with chest
X-ray or sputum cytology. No
controlled studies of spiral CT
reported. Recommended need for a
standardised and reproducible
approach to the performance and
reporting of CT examinations and
the evaluation and follow-up of
results. Impact of false positives
needed to be systematically
assessed. 
Humphrey,  Yes Yes Yes Yes No Lung cancer could be diagnosed at a 
200424 significantly ‘earlier stage’ than
currently occurs in clinical practice.
Unclear whether this will translate to
a mortality benefit.also identified a high proportion of stage I
disease. Resection rates were high, substantially
higher than the current UK resection rates of
below 10%.4,60
Is the increase in resection rates sufficient to imply
a reduction in disease-specific mortality? There is
evidence from the studies that substantial numbers
of participants in screening will die from other
causes, particularly cardiovascular disease.
Similarly, the Japanese studies including non-
smokers29,51 identified a rate of cancer similar
among smokers and non-smokers. In the non-
smokers, the tumours identified were
pathologically well-differentiated adenocarcinomas
or bronchoalveolar carcinomas and grew at a
substantially slower rate than tumours in smokers,
with mean doubling times in excess of 800 days.43
The frequency of these tumours decreased in
subsequent screening rounds. This may support
the notion of baseline screening detecting a
substantial number of slow-growing tumours. The
natural history of these well-differentiated small,
screening-detected cancers is not yet well
understood. 
Large numbers of positive CT examinations were
reported, particularly at baseline screening. As a
result, a high proportion of screening participants
underwent further follow-up, either by further CT
or even by biopsy. All studies reported some
biopsies conducted for what transpired to be
benign disease. The rate of biopsy for benign
disease varied with different follow-up protocols.
Intensive follow-up with CT appears to reduce the
number of biopsies. PET and CT enhanced by
intravenous contrast medium enabled further
classification of risk to reduce biopsy rates.
However, only one study reported the systematic
use of PET50 and identified a number of cases
where the use of PET led to biopsy of benign
disease.
Adverse event reporting was universally poor in
the studies. None of the studies explored the
psychological or quality of life impact of the high
false-positive rates of screening CT, in particular
the potentially long periods of uncertainty while
follow-up was undertaken. Only one study
reported the adverse events associated with
diagnostic investigation. Surgical outcomes were
poorly reported. None of the studies was of
sufficient duration to assess the risk associated
with radiation exposure.
In conclusion, the current evidence base for CT
screening for lung cancer is insufficient to
demonstrate clinical effectiveness in terms of a
reduction in mortality. The ongoing uncontrolled
studies may provide a better understanding of the
natural history of CT screening detected NCNs
and lung cancer. To demonstrate a reduction in
mortality, RCT evidence will be necessary.
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The aim of this chapter is to consider critically
published evidence relating to the relative cost-
effectiveness of population screening programmes
for lung cancer using CT. The results of a
systematic review of the published literature
focusing on the identification of studies that
consider the cost-effectiveness of different
population screening programmes are reported.
Six studies are included in the review and are
limited to the comparison between low-dose
helical CT (screening) and usual care (no
screening). Their conclusions depend on whether
it is accepted that screening for lung cancer in
high-risk populations can lead to improved
survival and a reduction in mortality. 
Review of economic literature
The aim of this section is to summarise published
cost-effectiveness analyses of population lung
cancer screening programmes. Two reviewers (CB
and RDV) searched the literature as outlined in
Chapter 3 and Appendix 2 to identify relevant
cost-effectiveness evidence. Two reviewers (ABol
and CM) then independently assessed the studies
to be included in the review. 
Identification of studies
Two reviewers examined all the titles and abstracts
of the 1041 articles identified by the electronic
search, and 23 were considered potentially
relevant to the cost-effectiveness review. A search
of the references cited in the included papers did
not identify any further articles for review. These
articles were then assessed for inclusion in the
review using the criteria below.
  inclusion criteria:
– full economic evaluation
– explicit synthesis of costs and outcomes in a
cost-effectiveness ratio
– CT (intervention)
  exclusion criteria:
– no attempt to synthesise costs and benefits
– reports, letters, editorials, reviews,
commentaries or methodological papers
– non-English language.
Data relating to economic study design, findings
and quality were extracted by one reviewer and
independently checked for accuracy by a second
reviewer. All details were extracted on pretested
data extraction forms. All of the studies were
quality assessed using criteria updated from the
checklist developed by Drummond and
colleagues.66
Quantity and quality of research
available
Only six of the studies assessed for inclusion met
the criteria and were considered further
below.67–72 Seventeen studies were excluded from
the review for the following reasons: published in
Japanese language (2); discussion papers only (3);
reviews of previously published studies (4); letters
to the editor (3); inappropriate comparators (3)
and technology assessment reports (2). For further
details, see Table 7. Several of the 17 excluded
papers discuss the findings from the six studies
included in the review.
The six studies included in the review were full
economic evaluations of population screening
programmes for lung cancer using CT. Overall the
quality of the published papers was difficult to
judge for two reasons. First, reporting of the
economic and mathematical models used in these
studies was poor; this means that replication and
verification by the reader is not possible, as the
inner workings of the models are not disclosed.
Second, lack of clinical effectiveness data means
that there is no ‘right’ way to answer the research
question of interest. As a result, it is difficult to
judge which of the papers contained the most
valid assumptions or used the most appropriate
analytical methods.
In summary, all of the authors adequately
described the research question and
comprehensively described the relevant
comparators. However, few papers included full
and explicit discussion of the identification,
measurement and valuation of the range of costs
and benefits included in the analyses. Economic
and mathematical models were used in all of the
papers to produce cost-effectiveness ratios.
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Chapter 4
Economic literature review of CT screening for 
lung cancerUnfortunately, the majority of authors did not
provide sufficient details of structural assumptions,
definitions of variables, parameter estimates or
equations relating variables to one another to
permit intelligent peer review to be undertaken.
Appropriate use of discounting, sensitivity analysis
and incremental analysis was conducted in all but
one study. Surprisingly, few of the authors
included references to previously published cost-
effectiveness results.
Clearly, the quality of the cost-effectiveness studies
included in the review was less than satisfactory.
See Table 8 for details of study quality.
Characteristics of economic
papers (Table 9)
The majority of the included economic evaluations
were incremental cost-effectiveness analyses and
reported outcomes in terms of incremental cost
per life-year gained. One study presented results
in terms of both incremental cost per life-year
gained and incremental cost per quality-adjusted
life-year (QALY) gained.71 One study reported
only incremental cost–utility analysis results,69 and
one study67 reported only “total cost for one life
saved” and “total cost per mean life expectancy of
a patient saved”. One study was set in Japan67 and
the others were carried out in the USA. The
frequency of CT screening ranged from a one-off
CT examination71 to an annual CT examination
over a 20-year period.69 Correspondingly, patient
follow-up varied from a 12-month period72 to a
40-year period.69 CT was an intervention in all of
the evaluations and no screening was a
comparator. The study population was not
uniform across the studies. Four out of six
studies69–72 evaluated CT screening for lung
cancer in a population of high-risk individuals.
Economic evaluation models (Table 10)
All of the papers were based on mathematical67 or
economic models. The economic models were
primarily decision-analytic models. The
perspectives used in the models, and therefore in
the economic analyses, varied from study to study.
One study69 described its viewpoint as societal, yet
failed to estimate the costs of lost productivity and
disability associated with screening and included
informal care costs. The majority of authors
outlined the major assumptions of their models.
However, on closer inspection, much of the
important detail was lacking. Only two studies69,72
incorporated some form of bias assessment into
their models. Two studies addressed bias in the
sensitivity analysis,70,71 while the remainder did
Economic literature review of CT screening for lung cancer
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TABLE 7 Summary of included/excluded studies
Study Included/ Reason
excluded
Institute for Clinical Systems Improvement, 200173 Excluded Report
Gambhir, 199874 Excluded Not screening
Wisnivesky, 200372 Included Full economic evaluation
Marshall, 200171 Included Full economic evaluation
Caro, 200075 Excluded No CT examination as comparator
Okamoto, 200067 Included Full economic evaluation
Klittich, 200276 Excluded Review of published studies
Hunink, 200377 Excluded Review of published studies 
Chirikos, 200378 Excluded Letter
Petty, 200379 Excluded Letter
Reich, 200380 Excluded Letter
Mahadevia, 200369 Included Full economic evaluation
Chirikos, 200268 Included Full economic evaluation
Marshall, 200170 Included Full economic evaluation
Iinuma, 199481 Excluded Japanese language
Anon, 200382 Excluded Review of published study
Bechtel, 200383 Excluded Discussion
Trow, 200384 Excluded Review of published economic evaluation
Asakura, 199985 Excluded Japanese language
Baba, 199886 Excluded No CT examination as comparator
Swedish Council on Technology Assessment in Health Care, 200387 Excluded Report
Grannis, 200288 Excluded Discussion
Grann, 200389 Excluded DiscussionHealth Technology Assessment 2006; Vol. 10: No. 3
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c
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c
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c
e
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o
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a
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r
 
i
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I
C
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s
–
 
N
o
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r
e
g
a
t
e
 
c
o
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t
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–
 
V
a
l
u
a
t
i
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o
f
 
–
 
N
o
 
L
Y
G
 
p
r
e
s
e
n
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e
d
c
r
e
d
i
b
l
y
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e
s
e
n
t
e
d
p
r
e
s
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t
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e
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n
t
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n
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h
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o
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s
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d
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n
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e
n
c
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s
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✕
N
o
t
 
s
t
a
t
e
d
 
 
–
 
C
o
s
t
s
 
o
n
l
y
 
(
3
%
)
–
 
C
o
s
t
s
 
o
n
l
y
 
(
7
.
5
%
)
 
f
o
r
 
d
i
f
f
e
r
e
n
t
i
a
l
 
t
i
m
i
n
g
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
a
n
a
l
y
s
i
s
✕
R
a
t
i
o
s
 
o
n
l
y
 
 
 
 
 
S
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
i
s
 
p
e
r
f
o
r
m
e
d
X
 
N
o
n
e
 
 
 
 
 
I
n
c
l
u
s
i
v
e
 
d
i
s
c
u
s
s
i
o
n
 
o
f
 
s
t
u
d
y
 
r
e
s
u
l
t
s
 
–
 
O
n
l
y
 
t
w
o
 
r
e
f
e
r
e
n
c
e
s
 
 
–
 
D
o
e
s
 
n
o
t
 
d
i
s
c
u
s
s
 
–
 
D
o
e
s
 
n
o
t
 
d
i
s
c
u
s
s
 
–
 
D
o
e
s
 
n
o
t
 
d
i
s
c
u
s
s
 
M
a
r
s
h
a
l
l
 
(
2
0
0
0
)
r
e
l
e
v
a
n
t
 
p
r
e
v
i
o
u
s
 
r
e
l
e
v
a
n
t
 
p
r
e
v
i
o
u
s
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
r
e
p
o
r
t
s
r
e
p
o
r
t
s
 
,
 
a
p
p
r
o
p
r
i
a
t
e
l
y
 
d
i
s
c
u
s
s
e
d
;
 
–
,
 
p
a
r
t
i
a
l
l
y
/
m
a
y
b
e
 
d
i
s
c
u
s
s
e
d
;
 
?
,
 
c
a
n
n
o
t
 
t
e
l
l
;
 
✕
,
 
n
o
t
 
s
t
a
t
e
d
;
 
I
C
E
R
,
 
i
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
r
a
t
i
o
;
 
L
Y
G
,
 
l
i
f
e
-
y
e
a
r
s
 
g
a
i
n
e
d
.not appear to consider the effect of bias on the
cost-effectiveness results. Estimates of life
expectancy are integral to the calculation of the
cost-effectiveness analysis, yet two studies67,69 did
not explicitly state what method was used in their
analyses. 
Cost data and cost data sources 
(Table 11)
All of the studies explicitly reported the price year
and the currency used, except for one67 which
failed to state the price year. Overall, for the
majority of studies, the costs should have been
comparable as the price years were within a 3-year
band (1999–2001). The key categories of costs
were similar across the studies and can be divided
into screening costs and treatment costs. Some
studies were very inclusive and included the cost
of managing non-cancer patients over the age of
6570,71 and monitoring of indeterminate
nodules.69 Examples of costs included in the
studies are presented in Tables 12 and 13. Most of
the studies relied on the published literature
(including Medicare reimbursement rates) for
sources of cost data. One study72 used registry data
to identify newly diagnosed patients and then
used the hospital finance database to allocate
costs. Individual patient costing was not reported
by any of the authors. Four studies used a 3%
discount rate and one study68 used a 7.5% rate.
The majority of the studies presented total and
incremental costs. However, one study68 only
presented screening and treatment costs per lung
cancer detected. 
Economic literature review of CT screening for lung cancer
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TABLE 9 Characteristics of economic studies
Study Type of evaluation  Interventions  Study population Country Period of study
and synthesis
Okamoto, 200067 CEA; total cost for  Mass screening  Individuals aged  Japan 5 years
one life saved; total  (indirect chest X-ray  40–84 years
cost for mean life  for all screened and 
expectancy saved sputum cytology for 
high-risk individuals) in 
1983 and in 1993 and 
CT option
Marshall, 200171 Incremental CEA;  Baseline scan with  Hypothetical cohort  USA 5 years
incremental cost  spiral CT vs no  of 100,000 high-risk 
per LYG screening individuals 
(60–74 years)
Marshall, 200170 Incremental CEA and  Annual scan for  Hypothetical cohort of  USA 5 years
CUA; incremental  5 years with spiral  100,000 high-risk 
cost per life-year  CT vs no screening individuals (60–74 years)
saved and cost per 
QALY saved
Wisnivesky, 200372 Incremental CEA;  Single scan with spiral  High-risk individuals  USA Costs were 
incremental cost per  CT vs no screening (aged ≥ 60 years, at  restricted to
life-year saved least 10 patient-years  1 year; benefits 
and no other  unclear
malignancies)
Chirikos, 200268 Incremental CEA;  Five annual screens  Hypothetical cohort  USA 15 years
incremental cost per  with spiral CT vs no  of screened and 
LYG; cost per cancer  screening unscreened patients 
case detected (general population 
≥ 45–74 years)
Mahadevia, 200369 Incremental CUA;  Annual screen  Hypothetical cohorts  USA 40 years
incremental cost  (20 years) with spiral  of 100,000 current, 
per QALY gained CT vs no screening quitting and former 
heavy smokers 
(aged ≥ 60 years, 
55% male)
CEA, cost-effectiveness analysis; CUA, cost–utility analysis; QALY, quality-adjusted life-year.Health Technology Assessment 2006; Vol. 10: No. 3
29
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c
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c
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c
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p
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b
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c
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.
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c
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f
r
o
m
 
a
n
n
u
a
l
s
u
r
v
i
v
a
l
 
r
a
t
e
s
 
f
o
r
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p
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d
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c
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p
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b
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b
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i
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v
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i
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p
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c
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Only two short-duration RCTs of screening for
lung cancer using CT exist. The majority of the
published studies were, therefore, based on
prospective, uncontrolled cohort studies. Five out
of six studies, excluding Okamoto,67 appear to use
the Surveillance, Epidemiology and End Results
(SEER) registry, a public-use database, to estimate
lung cancer incidence and mortality probabilities
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31
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TABLE 12 Examples of included screening and diagnostic cost items
Study Screening and diagnostic items Cost (US$)
Wisnivesky, 200372 LDCT examination 165
HRCT examination 300
Limited CT examination 65
Fine-needle aspiration 500
Marshall, 200171 LDCT examination 180
HRCT examination 311
Follow-up (3, 6, 9, 12 months) 311
Biopsy 460
Okamoto, 200067 Primary CT screening 30
Detailed CT examination 107
Mahadevia, 200369 Helical CT examination 300
Follow-up diagnostic CT examination 429
Antibiotic course 158
Opportunity cost for cost of travel time 14
Marshall, 200170 Low-dose helical CT examination 150
HRCT examination 280
Thoracoscopy with biopsy 430
Office visit 30
Chirikos, 200268 Screening CT examination 291
Diagnostic CT examination 340
CT thorax without contrast material 291
CT thorax with contrast material 340
CT thorax without and with contrast material 416
CT guidance for needle biopsy  382
Biopsy, lung of mediastinum, percutaneous needle 126
CT-guided biopsy procedure, total 507
TABLE 13 Examples of included cancer care cost items
Study Cancer care items Cost (US$)
Wisnivesky, 200372 NSCLC stage I 20,100
NSCLC stage II 23,300
NSCLC stage III 31,800
NSCLC stage IV 32,700
NSCLC stage V 25,900
Okamoto, 200067 Average cost of therapy for CT screen-detected patients 7,200
Average cost of therapy for outpatients (CT screened) 21,500
Mahadevia, 200369 Localised NSCLC, surviving 1 year 43,900
Localised NSCLC, dying 1 year 66,500
Localised NSCLC, ongoing year 4,500
Localised NSCLC, terminal year 30,400
Marshall, 200170 Annual cost of management, stage I 16,242
Annual cost of management, stage II 28,731
Annual cost of management, stage III 28,731
Annual cost of management, stage IV 56,527
Annual cost of management without LC 6,146Economic literature review of CT screening for lung cancer
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.for the unscreened population. Three studies70–72
used data from ELCAP to estimate probabilities
for the screened population (e.g. distribution of
tumours detected in screened population).
Mahadevia and colleagues69 used data from four
previously published cohort studies to derive
weighted probabilities for the screened
population. One study68 used data from a range of
previously published studies including ELCAP for
the screened population, whereas the remaining
study67 does not state the source of probabilities
for any population. A list of probability data used
in the studies can be found in Table 14. Where
stated, estimates of life-years gained were taken
from national survival rates for the US population.
Only two studies69,70 used quality of life data to
describe the impact of lung cancer screening on
patients and both studies used quality of life data
from previously published sources. Only one
study69 did not report outcomes in terms of life-
years saved, yet it reported absolute and relative
reductions in deaths and cost per QALY gained.
Cost-effectiveness ratios (Table 15)
The ICERs varied considerably across all of the
papers. Incremental life-years gained varied from
US$250072 to $90,02268 and incremental cost per
QALY ranged from US$19,50070 to $2,322,700.69
All but one67 of the studies used extensive
sensitivity analysis to determine the robustness of
the cost-effectiveness results. Specific variables that
may lead to higher cost-effectiveness ratios
included low prevalence rate, reduced survival
(e.g. introduction of 1-year lead-time bias),
increased cost of diagnostic tests, increase in the
number of patients overdiagnosed and a less than
100% adherence to the screening programme. Of
the six papers included in the review, four of the
authors concluded that screening for lung cancer
with CT could be a cost-effective approach. One
author71 was more cautious and stated that
although at the time of the study there was
insufficient evidence of costs and benefits, there
was the possibility that lung cancer screening with
CT could be cost-effective. Finally, Mahadevia and
colleagues69 argued against the introduction of a
mass-screening programme for lung cancer using
CT. It could be argued that the studies varied too
much to allow a valid comparison of their results.
Summary of evidence
From the literature review presented above, it was
very difficult to draw any conclusions on whether
or not screening for lung cancer using CT,
compared with usual care, is a cost-effective
option. All of the papers in the review approached
the research question from different starting
points. To illustrate, frequency of screening and
definitions of high-risk groups varied across the
studies. None of the papers in the review was set
in the UK, and this means that their relevance to
the NHS was somewhat limited. Given the paucity
of UK data available, it was difficult to compare
patterns of healthcare and possible differences in
tumour behaviour between the UK and other
countries.
More importantly, there was wide variation in the
magnitude of the cost-effectiveness ratios. This
disparity in cost-effectiveness ratios was not
surprising as the authors described markedly
different logistical approaches to screening and
often incorporated quite different assumptions
about survival and mortality. None of the
economic evaluations discussed the costs of setting
up (e.g. recruitment costs) or administering (e.g.
purchase of new diagnostic equipment) a
population screening programme, and it was
assumed that the costs and benefits reported were
those associated with a fully established
programme. The actual size of the population to
be screened was not explored in any of the papers,
nor was the impact on healthcare budgets
discussed. In addition, none of the papers
estimated the benefits, harms and significant costs
of incidental diagnoses obtained through
screening. 
There is currently a resurgence of interest in
screening for lung cancer.90 Previously, screening
for lung cancer focused on the use of radiography
and sputum cytology analyses.73 However, none of
these studies was able to demonstrate a decrease
in disease-specific mortality.87 Recently, there has
been a worldwide call for the re-evaluation of
screening programmes for lung cancer. There are
three important reasons for this. First, it is argued
that these previous studies were flawed in both
methodology and interpretation.91 Second, new
technologies have been developed that may
improve the effectiveness of screening for lung
cancer,90 and third, there is increased public
demand for these technologies, particularly in the
USA, as a result of aggressive consumer
advertising.92
Lack of clinical evidence
Advising patients on the merits of lung cancer
screening is difficult given the current lack of
evidence,93 both clinical and economic. According
Economic literature review of CT screening for lung cancer
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36to Patz and colleagues,90 a successful screening
programme must be able to offer patients effective
treatments that can reduce mortality. To date,
there is no published evidence to support the
assumption that screening for lung cancer leads to
reduced mortality rates. However, there is
evidence to suggest that screening for lung cancer
can improve the stage distribution of tumours
identified.94 This means that more early-stage
disease can be detected. However, whether or not
a stage shift occurs90 and whether or not detecting
lung cancer early alters the natural history of the
disease25 are very much subjects of intense debate.
In addition, the majority of peripherally located
tumours are visible by CT, but the majority of
centrally located tumours are radiologically
occult.95 The focus of screening programmes
therefore appears to be the detection of
peripheral cancers, although detection of centrally
located lung cancers is still important.96 The
implications of this for the screened and
unscreened populations were not discussed in any
of the included studies. 
Stage distribution
The studies included in the literature review
assumed that the improved stage distribution did
take place and there was an implicit assumption
that this translated into a mortality benefit.
However, only Mahadevia and colleagues69
explicitly quantified the effect of varying this stage
shift. Chirikos and colleagues68 simply mentioned
that the cost-effectiveness ratio was sensitive to the
number of early-stage cancers detected.
Quality of life
Only two of the included studies69,70 addressed
quality of life issues and conducted cost–utility
analyses. Both papers reported utility values from
a previously published paper.97 Neither of the
studies explicitly mentioned that these utility
values were not elicited directly from patients
suffering from lung cancer, but were compiled for
two hypothetical NSCLC patients. Consideration
of quality of life issues in cancer studies is
important; however, the methodological rigour
with which utilities are measured must be
maintained.98
Bias
It is reported that mortality is the true test of the
effectiveness of screening for lung cancer,99 as
changes in mortality rates are unconfounded by
bias. Survival rates are often reported in screening
studies and used in cost-effectiveness reports.
However, survival rates are said to be subject to
lead-time bias, length bias and over-diagnosis bias,
as defined in Chapter 2 (p. 8).90 Whether or not
these biases are incorporated into the cost-
effectiveness analysis, and the analytical methods
chosen, can markedly affect the cost-effectiveness
ratios produced, as demonstrated by the results of
the included studies. If these biases are omitted
from the analysis, then the survival (and mortality)
benefit may be overestimated and vice versa. The
methods used for dealing with bias in the included
studies were not transparent enough to allow
verification by the reader.
Harm must be included in the economic decision-
making framework. Economic evaluation is often
labelled as a systematic and objective framework
for decision-making as it allows a full investigation
of the costs and benefits of the healthcare
technologies under scrutiny. Assessing the costs
and benefits of population screening for lung
cancer, therefore, requires careful consideration of
the harms associated with screening, including the
mortality and morbidity associated with the
verification of indeterminate or falsely positive
nodules, radiological risk and reduced
participation in future screening programmes.
False positives
One of the major criticisms of screening
programmes for lung cancer is the relatively high
false-positive rate.77 Only Mahadevia and
colleagues69 reported the number of unnecessary
biopsies and surgeries associated with their
screening programme. The false-positive rate of
screening may be very high93 and this is possibly
one of the overwhelming arguments for not
adopting a national screening programme 
in the UK. 
Radiological risk
No incorporation of radiological risk was
performed by any of the authors of the included
studies. This was an important omission as
radiation exposure (including follow-up CT
examinations) may account for more deaths than
lives saved by the screening programme.93 Indeed,
a recent report reveals that the radiation risks
potentially associated with low-dose CT screening
of adult smokers for lung cancer are substantial.100
Adherence
Finally, some argue that high-risk individuals who
have a negative screen may perceive this as
reinforcing their belief that their lifestyle does not
require modification and that this will lead to
reduced participation in screening programmes in
the future. Linked to this is the explicit
consideration of adherence in screening
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compliance and persistence,101adherence is
another factor that can influence the size of the
cost-effectiveness ratio and was not explained in
depth by any of the authors. 
Generalisability
The generalisability of the results of the cost-
effectiveness analyses included in this review must
be explored. From a clinical perspective, as
MacRedmond and colleagues52 point out, it is very
difficult to transfer the results of screening
programmes from one country to another. For
example, most of the included studies in the
review used prevalence data from the US ELCAP
study; this study reports a prevalence of CT-
detected lung cancer of 2.7%.94 In contrast, a
study set in Ireland52 found the prevalence of lung
cancer detected in a population of asymptomatic
high-risk smokers to be only 0.46%. 
In terms of cost-effectiveness, the country of origin
of the study is also very important. For example,
one country may have a very aggressive follow-up
policy after screening and this will be more
expensive than a less aggressive policy. Year of the
study is also central to the cost-effectiveness
debate, especially where the technology of interest
is rapidly evolving. All of the studies in the review
will therefore need to be updated and their results
reconsidered in the near future.89
Finally, each screening programme needs to be
evaluated in terms of clinical and cost-effectiveness
on its own merits. Generalisability will be limited
when even slightly different screening
programmes are being compared. For example, it
has been suggested that patients should undergo
individual counselling from their GP before
screening for lung cancer to discuss possible
outcomes.102 Whether or not these costs are
included in or excluded from a cost-effectiveness
analysis would influence the size of the cost-
effectiveness ratio.
Conclusion
In conclusion, there are many issues that remain
unresolved in the debate over the true cost-
effectiveness of lung cancer screening
programmes. Before any definitive screening
recommendations can be proposed, careful
analysis of current and ongoing CT studies must
be conducted; in addition, more complete and
transparent cost-effectiveness analyses are
required.90 The introduction of a population-
screening programme should depend on
confirmation that screening for lung cancer using
CT does lead to a reduction in mortality.
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The central concern of this chapter is to explore
how our current understanding and the corpus of
reliable evidence might support a meaningful
economic evaluation of lung cancer screening.
Through assessment of the published economic
studies already described and the modelling
methods used, it has been concluded that it is not
currently possible to perform a rigorous analysis
that could yield useful information to inform
decision-making in this important area of public
policy.
The principal factors leading to this conclusion
are:
  the lack of high-quality direct evidence of
benefit (i.e. extension of life)
  the high risk of harm through large numbers of
false-positive detections
  the currently weak understanding of processes
involved in the origin and development of
cancerous lesions amenable to screening, which
prevents modelling of screening interventions
with any confidence.
The following subsections describe and discuss
various problems encountered in attempting to
construct a mathematical and economic model of
screening for NSCLC to demonstrate why the
authors believe that attempting a full economic
assessment is premature. An indication of the type
of evidence that would be required to redress the
perceived shortcomings is also given.
Lung cancer disease modelling
The economic evaluation of a screening
programme for any disease or condition involves a
careful comparison of the anticipated health-
related costs and outcomes associated with two or
more alternative possible ‘futures’, governed by the
presence or absence of a defined screening
programme. Regardless of the availability of high-
quality RCT evidence of efficacy (but particularly
when this is lacking), it is important to have a good
understanding of how the disease originates,
develops and progresses. Where such knowledge is
available, it is best represented in the form of a
mathematical model that allows the impact of a
screening programme to be projected and
quantified over extended periods (ideally the
remaining lifetime of the individuals affected).
However, the process of formulating such a model
imposes a discipline on the researcher and exposes
deficiencies in both evidence and logic which, if
not rectified, render the whole exercise ineffectual.
The disease process
It is generally understood that any cancer
originates from a single anomalous cell that begins
to grow and replicate in an uncontrolled manner.
In the early stages of growth (for solid tumours)
the colony of affected cells is localised within a
single organ and is not detectable clinically or by
imaging technologies. In the absence of active
screening (whether opportunistic or systematic)
most cases are not identified until patients present
with suggestive clinical symptoms. Current
thinking assumes that tumours grow at an
exponential rate, often measured in terms of a
‘doubling time’. However, it is not clear whether
this is a realistic reflection of the normal process of
cell replication, or is merely a convenient mode of
description.
The wide range of disease severity observed in
patients with newly diagnosed lung cancer
suggests strongly that the development of
symptoms (and therefore the stage of disease
progression at which the cancer is normally
diagnosed) is related to, but not determined by,
tumour size.
The present case is concerned solely with NSCLC
(which constitutes around 83% of lung cancer
cases), since early detection of NSCLC is
associated with better treatment outcomes from
surgical intervention, whereas the same is not true
for SCLC.103 However, the proposed screening
technology only applies to cancers developing in
the areas of the lung distant from the bronchi
(where tumours are largely undetectable by CT).
These generally appear as of any size from 1 mm
to over 40 mm. Screening for such nodules is
expected to be effective by allowing them to be
removed surgically before they are able to grow
and metastasise to adjoining or distant organs.
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Chapter 5
Economic evaluation of lung cancer screeningA stylised representation of the natural
development, progression and detection of
NSCLC is shown in Figure 2. As a potentially
cancerous nodule grows it moves along the scale of
disease staging (left to right), and in parallel the
probability of emergent symptoms resulting in
detection (p1–p4) also increases. The balance of
symptomatic disease detection rates, subsequent
disease (i.e. stage) progression rates (q12–q34) and
stage-related mortality rates governs the relative
proportions of diagnosed patients in the various
disease stages at any time after detection.
However, in this schema only the stage-specific
mortality rates are directly measurable, and
human studies to obtain the missing transition
rate information would be unethical, since this
would require treatment to be withheld from
patients with known disease.
In addition, this conceptual model is based on
assumptions that may be vulnerable to challenge.
In particular, it is assumed that malignant NCNs
will continue to develop steadily unless they are
surgically removed. Yet it may be the case that
some will stabilise, shrink or grow so slowly, if left
in situ, that not all will develop into lethal lesions.
This suggests that a more complex model
structure would be needed, requiring additional
parameter values to be estimated for which no
evidence currently exists.
Patient diversity and bias
NSCLC is not a single disease, but a mixture of
related types of cancer affecting different lung
cells in a variety of ways. In addition, there is clear
evidence of wide variations in the aggression of
lesions affecting different patients, so that
doubling times for tumours have been reported of
under 80 days and more than 400 days.43 Under
the simple model of lung cancer development,
doubling time is necessarily a positive number of
days, and therefore its probability distribution is
likely to be heavily skewed. Non-homogeneity to
this degree calls into question the reliability of any
disease modelling based on simple average
parameter values. It also gives rise to the three
types of bias often associated with studies of
screening programmes and described in Chapter
2 (p. 8): over-diagnosis, length bias and lead-time
bias.
A well-formulated disease progression model that
fully reflected this essential lack of homogeneity
would be automatically free of these biases, and
indeed could be used to estimate the magnitude of
bias observable in clinical studies. However, none
of the models so far published for economic
evaluation of screening is of this type. Therefore,
authors have been obliged to introduce artificial
adjustment factors in an attempt to correct for
these biases. Yet the absence of reliable evidence
to support calibration of a disease progression
Economic evaluation of lung cancer screening
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Size of nodule
Diagnosed
lung cancer
Stage 1 Stage 2 Stage 3 Stage 4
Death
p1 p2 Detection p3 p4
q12 q23 q34
FIGURE 2 Stylised representation of tumour growth, symptomatic detection and disease progression in an unscreened populationmodel applies equally to estimation of the three
types of bias, and the literature includes
considerable debate and controversy concerning
the importance of bias in relation to lung cancer
screening.99,104–107
Stage shift and estimated survival
As noted in the review of clinical studies, there is
currently no evidence that screening for lung
cancer results in extended life expectancy in any
population. Until such evidence is presented, the
only way that a case can be made for screening is
through indirect inference, assuming that
intermediate outcomes (cases detected) can be
converted with confidence into true outcome
gains. Fundamental to all the published models is
the notion of ‘stage shift’, which is used as the
primary basis for estimating the expected gain in
average survival and life-years. Since screening
studies frequently show a preponderance of
patients in the early stages of disease, compared
with patients identified clinically, it is assumed that
this alteration in the distribution of disease stage
can be converted directly into improved survival
using standard disease and treatment-specific
register statistics.
Although plausible, this assumption is by no
means free of suspicion. At a practical level, the
survival estimates obtained from disease registers
are invariably dominated by data from unscreened
symptomatic patients. The biases noted above
virtually guarantee that the prognosis of the latter
patients at diagnosis is significantly different to
that of asymptomatic screening-detected patients,
even if all other factors are similar. This problem
has been recognised by one author,69 who invoked
the idea of ‘pseudo-stage shift’ to moderate the
size of simple stage shift in a sensitivity analysis.
Summary
The processes by which cancerous lesions arise,
develop and progress into symptomatic lung
cancer are not well understood or described.
Missing information prevents design of a reliable
disease model for unscreened disease. Modelling
the effects of screening involves making further
uncorroborated assumptions about disease
progression and screening efficacy.
Screening and treatment protocol
The published studies of lung cancer screening
and related economic evaluations have used a
variety of protocols for screening people for
disease, investigating suspicious screening results
and treating detected disease. The screening
protocol that the present authors consider to be
most appropriate in the UK is shown in Figure 3,
which can be compared to the equivalent patient
pathways for patients developing lung cancer in
the absence of screening (Figure 4). These
diagrams would form the basis for any future
detailed modelling. However, important choices
must be made before modelling and assessment in
a number of areas, as follows.
Selection of screened population
It is generally recognised that any screening
programme is most effective and cost-effective if
targeted on those individuals for whom there are
pre-existing risk factors present predisposing them
to significantly higher risk of developing the
disease. This means identifying relevant high-risk
demographic subgroups (age, gender and
ethnicity), as well as those whose lifestyle or
occupation involves exposure to carcinogenic agents
(e.g. tobacco smoke, asbestos). Only in Japan has
unselected screening for lung cancer in the adult
population been introduced. Elsewhere, some
prescreening selection process is undertaken,
generally involving medical or related
professionals assessing patient records or
questionnaires, or performing a clinical CT
examination. This has the effect of reducing the
number of unproductive screens carried out, but
also of increasing administration costs per
screened person.
A history of smoking is the most widely recognised
predisposing factor for lung cancer, with risks
increasing for both intensity of smoking [up to a
three-fold difference between heavy smokers
(>30 per day) and light smokers (<10 per day)]
and duration of smoking.108 The latter shows the
strongest effect, with relative risks of 15 or more
between lifelong smokers and non-smokers. In
combination, these factors may increase cancer
risks for smokers nearly 50-fold over non-smokers.
Smoking cessation leads to a progressive reduction
in lung cancer risks,7 but probably never to the
level experienced by non-smokers. Certain
occupational exposure appears to be associated
with increased risk of lung cancer, in particular
asbestos exposure. Other co-morbidities may also
be implicated, especially COPD.
In planning a screening programme it is
important to define the target population clearly
according to criteria easily implementable by those
charged with prescreening selection. The number
of eligible invitees and their risk of developing
lung cancer are crucial components in the
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Screening offered Present for screening
Helical CT screen
? Malignant/
large NCN
Indeterminate/
1–6 NCNs
HRCT scan
Negative –
no action
Abnormal
non-cancer
Refer for
relevant care
Negative –
discharge
? Indeterminate
result
? Malignant
nodules
Biopsy
for cancer
Growth
detected
Repeated HRCT scan
after 3 months
Repeated HRCT scan
after 12 months
Repeated HRCT scan
after 24 months
No growth detected –
discharge
Negative –
discharge
Cancer
confirmed
Assess fitness
for surgery
Fit for
surgery
Radical surgery
performed
Patient
‘cured’
Patient
not ‘cured’
Other
treatments
Not fit
for surgery
Follow-up care Death
FIGURE 3 Detection, confirmation and treatment protocol for screened NSCLCHealth Technology Assessment 2006; Vol. 10: No. 3
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Present
with symptoms
HRCT scan
? Malignant ? Indeterminate
result
Negative –
discharge
Biopsy
for cancer
Growth
detected
Repeat HRCT scan
after 3 months
Repeat HRCT scan
after 12 months
Repeat HRCT scan
after 24 months
No growth detected –
discharge
Cancer
confirmed
Negative –
discharge
Assess fitness
for surgery
Fit for
surgery
Radical surgery
performed
Patient
‘cured’
Patient
not ‘cured’
Other
treatments
Not fit
for surgery
Follow-up care Death
FIGURE 4 Detection, confirmation and treatment protocol for unscreened NSCLCestimation of both costs and cost-effectiveness. 
It may be necessary to carry out pilot surveys to
determine the former (especially where routine
data sources are incomplete or inaccurate) and
historic case series analyses may be used to
estimate the latter for a local area.
Summary
Selection of a high-risk subpopulation offers the
greatest chance of good public health and
economic outcomes for a lung cancer screening
programme. Smoking is the main risk factor for
selecting patients. However, performance of the
screening programme is dependent on good local
systems for identifying the highest risk individuals,
and pilot studies may be appropriate to confirm
feasibility.
Frequency and timing of screening
The first screen offered to a population (usually
referred to as a ‘baseline’ screen) is of a different
character to subsequent repeat screens. A baseline
screen detects prevalent asymptomatic cases of
lung cancer, some of which may have been present
and potentially detectable for several years.
Further screens (called ‘incidence’ screens) are
designed to detect new instances of lung cancer
that have arisen in the period since the last screen.
The yield from a baseline screen is bound to be
considerably greater than that obtained with other
screens, leading to better effectiveness and cost-
effectiveness results (assuming that true survival
benefit is established). The relationship between
baseline and interval screening yields is dependent
on all the unquantified disease parameters
referred to above, and is therefore difficult to
estimate consistently. In the ELCAP study94 the
rate of cancers detected at baseline was 2.7%,
whereas early results of repeat screening30
suggested a yield of 0.7%, i.e. a ratio of about 1:4.
Although it cannot be assumed that this figure is
generally valid, it may provide a useful basis for
illustrating the consequences of the distinction
between screen types.
Analysis of UK cancer incidence data combined
with life-table projections offers insights into the
age at which screening should start and the
frequency of subsequent interval screens. Figure 5
shows that the peak incidence rate of NSCLC in
the UK occurs at the age of 82 years for men and
78 for women. However, when converted into
annual numbers of new cases diagnosed (Figure 6),
the peak ages both occur at the age of 77 or
78 years, although the volume of disease in
women is only 65% of that experienced by men.
The potential for benefit from early detection and
treatment of NSCLC depends on the remaining
expected lifetime of individuals if they do not have
lung cancer. Individuals who receive curative
surgery as a result of screening detection could
expect to gain a substantial proportion of those
projected years (assuming again genuine survival
Economic evaluation of lung cancer screening
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FIGURE 5 Age-specific UK incidence rates of NSCLC in 2000. Sources: Lung cancer incidence statistics for 2000 (from
www.cancerresearchuk.org),2 combined with NSCLC:SCLC proportion from Clinical Outcomes Indicators 2002, CRAG Scottish
Executive103 and Office of Population Censuses and Surveys UK population estimates for 2001 (base-year 1994).gain from screening). Although there will be a
number of co-morbidities and other factors
moderating this effect, especially among smokers,
it is instructive to use the notion of ‘life-years at
risk’ to explore questions of the age at which
screening should start and how many screens
should take place at what intervals.
Figure 7 shows a similar pattern for life-years at
risk to Figure 6 (new cases), except that the peak
age has moved to 68 or 69 years and the potential
to benefit among women is now 76% of that of
men (owing to greater life expectancy of women).
This pattern is broadly proportionate to the gains
that may be expected from annual interval
screening about 1 year earlier.
If one wishes to consider the optimal timing of a
single baseline screen without any subsequent
rescreening, this effect can be approximated by
accumulating the annual risk over several previous
years. Using the ELCAP result, and accumulating 4
previous years’ incidence, it is found that the
greatest potential benefit occurs with a single screen
at the age of 70 for both men and women
(although any age between 66 and 74 ensures that
at least 90% of the maximum benefit is achieved).30
However, best economic results are likely when the
life-years gained per person screened are
maximised. Owing to the reducing number of
people in the population at older ages, the peak for
this measure occurs rather later, at 73 years of age.
Equivalent results for other screening programme
designs can be obtained by combining results from
baseline screens with (say) annual interval screens
over several years. This has the effect of moving
the starting age forward; thus, following a baseline
screen with five annual interval screens advances
the starting age by 2–3 years. However, because
the yield for interval screens is lower than for the
baseline screen, and each additional screen
includes screening times more distant from the
optimal-yield age, the incremental gain from each
extension of the programme diminishes.
These results have been confirmed by repeating the
analysis substituting NSCLC mean survival times by
stage, age and treatment derived from analysis of
the US SEER database for patients with NSCLC, in
place of UK life expectancy.109 The conclusions are
virtually identical, although it may be appropriate
to vary the optimum ages by 1 years (or 2 years at
most) to allow for possible lead-time bias.
Summary
If screening does lead to survival gains, then a
single screen at about 70 years of age can be
expected to provide the greatest gain in life-years
across the population. However, the best cost-
effectiveness of a single screen is likely at about
the age of 73. Adding further interval screens to a
baseline screen will incrementally increase overall
outcome gains, but steadily erode the cost-
effectiveness of the programme.
Health Technology Assessment 2006; Vol. 10: No. 3
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FIGURE 6 Age-specific UK incident cases of NSCLC in 2000. Sources: Lung cancer incidence statistics for 2000 (from
www.cancerresearchuk.org),2 combined with NSCLC:SCLC proportion from Clinical Outcomes Indicators 2002, CRAG Scottish
Executive103 and Office of Population Censuses and Surveys UK population estimates for 2001 (base-year 1994).Criteria for positive screen
Although screening test criteria vary between
published studies, the reviewers have assumed use
of the ELCAP scheme30 on the grounds that
ELCAP has furnished the data most widely used in
economic studies to date. A positive result involves
the identification of one to six NCNs suggestive of
possible lung cancer and requiring confirmatory
investigation. Patients with evident malignancy or
large nodules are referred directly for biopsy.
Those with diffuse disease (more than six NCNs,
diffuse bronchiectasis and/or ground-glass
opacities) are also referred for confirmation. Any
non-cancerous abnormalities are referred to the
appropriate specialist for follow-up and treatment.
Confirmation and diagnosis
Confirmation of screening-positive or suspicious
findings is by HRCT as soon as possible after the
screening test. Any confirmed probable
malignancy is referred for biopsy for a definitive
histological diagnosis and staging. If HRCT
clearly negates the initial screen suspicion, the
patient is discharged and re-entered into any
ongoing future screens defined by the screening
programme.
Follow-up of suspicious screens
For any patient undergoing a confirmatory HRCT
in whom suspicion remains, further HRCT
examinations are scheduled for 3, 12 and
24 months to look for evidence of nodule growth
suggestive of malignancy. If growth is found at any
stage, the patient is referred for biopsy; otherwise,
the patient is discharged to the normal screening
schedule.
Treatment and follow-up of detected
disease
Where biopsy fails to show any evidence of
malignancy the patient is discharged. For
confirmed cases of lung cancer, patients are
clinically assessed as to their fitness for surgery
appropriate to the stage and location of the
malignancy. Those deemed fit receive curative
surgery with conventional follow-up care, whereas
those unfit receive conventional modes of
supportive care appropriate to their needs.
Comment
Although the main screening protocol may be
defined quite clearly, the specification of other
aspects of care is more problematic. Ideally, a
realistic economic evaluation should reflect
‘normal’ or ‘average’ practice in UK hospitals, but
there is little reliable contemporary evidence
describing the balance between different types of
investigation or treatment and therefore the
resources used. Thus, the degree to which
bronchoscopy, thoracoscopy or guided
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FIGURE 7 Total years of expected remaining life at risk from newly diagnosed NSCLC by gender and single ages 40–90. 
Source: Interim Life Tables for UK based on 2001–2003, Government Actuary’s Department.transthoracic percutaneous needle biopsies are
used to confirm the diagnosis is unclear, as is the
use made of various other imaging techniques
when biopsy is not feasible or is unsuccessful (e.g.
PET). The techniques used are likely to vary with
the tumour location (central versus peripheral)
and patient tolerance of the procedure. Little is
also known of current UK practice in terms of the
various types of surgical intervention. The nature
and cost of ‘supportive care’ in lung cancer are
particularly poorly researched. Although
professional guidelines are of some interest, they
may be more indicative of future aspirations than
of the current state of clinical practice, which
should be the baseline from which any decision is
made.
Estimation of long-term survival
In the absence of direct evidence of survival gains,
the case for lung cancer screening depends on the
assumption that stage shift at detection and the
consequent change in mode of intervention (i.e.
increased use of curative surgery) lead to a better
prognosis for most patients. To quantify this effect
in the context of an economic evaluation it is
necessary to use statistics derived from
observational databases. Unfortunately the values
routinely reported in clinical or epidemiological
journals (median survival, survival at 1, 2 or
5 years) do not correspond to the measure
required for economic evaluation, the mean
estimated survival time. In particular, unless the
survival time distribution is symmetric, it is
probable that the median survival time will be a
biased and unreliable basis for estimating life
expectancy. 
A further problem arises when analysing data with
incomplete follow-up: although Kaplan–Meier
estimation with censoring yields mean survival
estimates, these often underestimate the true value
of the population mean owing to the absence of
sufficient data for extended follow-up. This
problem must be addressed by fitting parametric
models to the available data as a basis for
projecting all patients forward to the time of their
anticipated death. This procedure has been
applied to individual patient data available in the
SEER public-access database to derive mean
survival times for each combination of age,
gender, disease stage at diagnosis and principal
mode of treatment (i.e. surgery or not surgery).
The estimated mean survival in each case (for 
5-year age bands) was calculated using the
Kaplan–Meier technique, and then ordinary least
squares regression was used to fit a two-part model
involving one population component subject to
high mortality risk (simple exponential function
based on constant hazard), and a second
subpopulation exposed to lower risk and
represented by a Weibull distribution. Comparing
differences between the Kaplan–Meier and
parametric estimates (Figure 8) shows that for
estimates up to about 6 years the two approaches
yield very similar results, but beyond 6 years the
parametric method produces larger values as
expected, and is therefore to be preferred.
The SEER database is very widely used by
published authors as the basis for survival
calculations, partly because it is probably unique
in the size, range and quality of its data, and
partly because it is US specific and most
evaluations of lung cancer screening have been US
based.1 Unfortunately, there is no comparable data
source in the UK that would permit survival
estimates to be generated that are consistent with
UK case-mix profiles and treatment practices. In
the regional cancer registries staging information
is only available for a minority of patients, so it
would be impossible to estimate the consequences
of stage shift with any confidence. It is known
from summary statistics that the proportion of UK
lung cancer patients undergoing curative surgery
has been much lower than in the USA or
Europe,60,110,111 so that there are strong reasons to
believe that statistics derived from SEER will not
be transferable to a UK setting, since the case-mix
of patients benefiting from any stage shift would
be quite different from those benefiting in the
USA.
Summary
Estimation of survival gains indirectly through
assumptions about stage shift requires access to 
an appropriate and reliable source of data in the
UK, but this is not currently available. Use of the
SEER database for this purpose is subject to
serious and unquantifiable bias and so cannot be
justified.
Utility values for lung cancer
Whether survival gains are obtained directly from
an RCT or indirectly through stage shift
assumptions, it is necessary to convert these to
QALYs when performing a cost–utility analysis,
using a set of utility values obtained through a
validated generic methodology. As noted in the
previous section, there is no mention in the
published economic evaluations of an evidence-
Health Technology Assessment 2006; Vol. 10: No. 3
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sources ultimately derive values from a crude
hypothetical exercise in which no patient data
were used.97 However, a more recent Italian
study112 collected quality of life and utility data
(SF-36 and EuroQol) from 95 NSCLC patients in
15 hospitals. The authors quote mean EuroQol
values of 0.58 for lung cancer, and report univariate
binary variations for gender, age, time from
diagnosis, the presence of metastases and three
treatment modalities. Unfortunately, they did not
report any multivariate analysis to facilitate
estimation of utility by stage of disease, which
would be required for evaluation of any benefits of
lung cancer screening. Until comprehensive
patient studies are carried out to estimate utilities
for all the relevant lung cancer patient states using
an appropriate generic instrument, utilities have
to be ‘guessed’ or inferred by parallels with other
patient types. Under these circumstances any
cost–utility results will need to be subject to wide-
ranging sensitivity analysis, and may therefore fail
to command great confidence.
Summary
The lack of an evidence-based source for patient
utilities means that any cost–utility analysis of lung
cancer screening is likely to be subject to
substantial uncertainty.
Potential for harm
False-positive results
The false-positive rate of CT screening (i.e. the
complement of the test specificity) has an
important bearing both on the impact of
screening on the participating population and on
the costs associated with the programme. A meta-
analysis of test characteristics from published
studies69 shows a test sensitivity of 93% and
specificity of 83%. The relationship between the
number of cases of lung cancer correctly
identified and the number of participants with a
test result suggestive of cancer depends on the
underlying prevalence of the disease in the
population. For example, if the prevalence is
similar to that experienced in the baseline ELCAP
screen (where cancer was confirmed in 2.7% of
screens), then one should expect 14–16 false-
positive results for every case of lung cancer
found.30 However, if the prevalence was at the
level reported in Ireland52 (0.46%), then each
case of lung cancer occurs alongside 83–93 false
positives.
There are no definitive studies describing the
impact on screenees of a ‘suspicious’ result, but it
can be expected to involve considerable anxiety
for the individual and their family until further
Economic evaluation of lung cancer screening
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FIGURE 8 Comparison of Kaplan–Meier and parametric mean survival estimates for age, gender and treatment subgroupsinvestigations provide full reassurance (which may
take as long as 1 or even 2 years, depending on
the protocol used), and this may represent an
important (albeit limited) loss of quality of life and
personal utility. In addition, false-positive results
will lead to people affected undergoing several
additional HRCT examinations and perhaps extra
low-dose screening tests before doctors can be
confident that the patient is not suffering from a
clinically important lesion. These procedures add
substantially to the total cost of the screening
programme.
Adverse events
For a minority of false-positive detections, the
patient may undergo invasive diagnostic procedures
and even radical surgery for suspected malignancy,
and these procedures all carry the risk of serious
adverse events or even death. These risks, although
small, may have importance to economic analysis,
particularly as a single premature death (and the
life-years lost thereby) may have a marked impact
on ICERs. In ELCAP,32 only one biopsy was taken
from a patient with benign disease, and no patients
had other invasive surgery. By contrast, in Ireland,52
a total of eight procedures was carried out on seven
patients with benign disease (1.6%). It appears that
the probability of unnecessary thoracic surgery
varies widely between locations, and hence the risk
of serious adverse events leading to morbidity or
mortality may be significant, but is difficult to
predict.
Summary
A lung cancer screening programme is likely to
produce large numbers of suspicious cases that,
after further investigation, are found to be false
positives. These will incur additional costs for
diagnostic tests, and may involve many people in
periods of unwarranted anxiety. Furthermore, a
minority may undergo futile invasive procedures
with attendant risks of morbidity or mortality.
Radiological exposure
Brenner100 estimated the increased lifetime risk 
of lung cancer attributable to the additional
radiation exposure involved in LDCT screening.
He concluded that a single CT examination
would result in a negligible extra risk, but that
annual screening from the age of 50–75 is likely
to increase the lifetime incidence of lung cancer
by about 5% in women and about 1.5% in men.
He also remarks that delaying screening until 
the age of 60 sharply reduces the excess risk 
(by about 80%), and offering screening twice 
a year rather than annually cuts the extra risk 
by half.
Summary
A model used to evaluate and compare screening
schemes using multiple interval screens should
include a risk adjustment to reflect the increased
incidence rates associated with cumulative
radiological exposure.
Incidental findings
MacRedmond and colleagues52 highlighted the
importance of other morbidities identified in the
course of screening for lung cancer: in the Irish
study, incidental findings occurred in 61.5% of
patients, leading to many referrals to specialists in
respiratory medicine, cardiology and
gastroenterology. He reported that additional
healthcare costs were incurred for 49% of those
screened. It should not be any surprise to find
such co-morbidities where individuals are selected
for screening on account of their risk-factor
profile, even if the large number of incidental
cases reported may be exceptional. MacRedmond
notes that two-thirds of such disease was related to
cigarette smoking.
It is a matter for debate whether these incidental
discoveries contribute important additional health
benefits to the screening programme, or merely
increase anxiety for many people and their
families. What is not in dispute is that substantial
additional healthcare resources are required to
respond to these findings, some of which
constitute ‘new money’ and some are merely
incurred somewhat earlier than would otherwise
have been the case.
Summary
The selection of high-risk individuals for
invitation to screening increases the likelihood of
incidental findings of treatable disease in many
people. The extra costs and (dis)benefits of
treating these conditions should be included in an
economic evaluation of lung cancer screening.
Participation
The level of response to an invitation for a first
screening test is important in restricting the
quantity of prevalent disease that could be
detected, and is also important in assessing the
viability of a screening programme. However, it
should not affect the cost-effectiveness of the
programme greatly, unless response is biased in
relation to risk factors for lung cancer. By contrast,
the probability that individuals will drop out of
Health Technology Assessment 2006; Vol. 10: No. 3
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the economic assessment of programmes based on
continuing surveillance. The ELCAP experience of
repeat screening30 achieved a participation rate of
84% in the first round of annual repeat screens,
which increased to 88% after protocol exclusions.
Mahadevia and colleagues69 used 93.5% (a
weighted average of ELCAP and another US study
reported by Swensen49) for annual cumulative
participation rate. Regardless of the value used,
progressive erosion of the screened population
over several years can dramatically reduce the
likely yield of new detections in later years. After
10 years of annual repeat screens with a 10%
annual attrition rate, less than 35% of the original
cohort will still be participating, and only about
60% of the expected cancers will have been
detected. Since each extra year of screening
reduces the cost-effectiveness of the overall
programme, loss of participation can threaten the
economic case for multiyear screening. Experience
in Japan,37,44 where population-wide screening has
a longer history, suggests that attrition rates may
be considerably higher outside a study setting.
Summary
Participation rates in single-observation screening
are important for the viability of a programme,
but should not normally threaten its cost-
effectiveness. However, progressive loss of
participation in a series of repeat screenings can
impact adversely on both viability and cost-
effectiveness. Participation rates in studies 
may overestimate what is achievable in more
routine use.
Costs and resources
The ten main classes of healthcare resources and
costs required in a comprehensive economic
evaluation of lung cancer screening are detailed in
Table 16. None of the published economic studies
encompasses all elements. There are important
gaps in the availability of information applicable
to a UK context, and new data would need to be
collected via clinical studies or surveys in at least
six areas. Cost models that are based on phases of
patient experience have been developed for the
US health system,72,113,114 but cannot be used
directly in the UK without recalibration to NHS-
linked individual patient data.
Summary
There are serious shortcomings in the economic
data currently available in the UK concerning
treatment of lung cancer patients. New research is
required to provide information needed for a
comprehensive economic assessment of lung
cancer screening in the UK.
Conclusions
This chapter has considered several issues of
importance to researchers attempting an economic
evaluation of screening for lung cancer using
LDCT scanning. It has focused especially on the
evidential and data requirements for constructing
a suitable disease, screening and treatment model
for such an evaluation. In the process, serious
deficiencies in the type and quality of information
from UK sources were identified. One or two such
problems may sometimes be addressed through
targeted scenario analysis, but the broad range of
deficiencies in this instance renders such an
approach infeasible.
The most severe problem is the lack of high-
quality RCTs demonstrating directly that the
screening programme is effective in reducing
mortality or morbidity. Claims to efficacy have to
be based on inference from intermediate
outcomes, and the required logic, although
convincing to some, is vulnerable to challenge.
The weaknesses in this argument are directly
related to gaps in our understanding of the early
natural history of NSCLC, concerning the growth
dynamics of NCNs and their development into
clinical lesions. These weaknesses become
apparent when attempting to structure and
populate a mathematical model.
Efficacy is at the heart of any economic assessment
of a health technology: if the evidence does not
support health gains in either the quantity or
quality of life, and there are net additional costs
incurred (as is very likely with lung cancer
screening), then it is highly improbable that
screening can ever be shown to be cost-effective.
Conversely, if lung cancer screening can be shown
to generate significant extension of life with only
modest additional cost per patient, then cost-
effectiveness will very probably be demonstrable in
most circumstances. Thus, the need for
unambiguous RCT evidence of screening efficacy
in a UK setting is paramount. Closely related to
efficacy is reliable information concerning the
prevalence and incidence of potentially identifiable
NSCLC in selected populations. The disparity in
prevalence findings between the Irish study and
USA ELCAP studies raises serious doubts about the
extent of detectable disease that may be expected
in the UK. This is important since the cost-
Economic evaluation of lung cancer screening
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TABLE 16 Elements of health-related cost required for evaluation of lung cancer screening
Cost element Description Comment Resource and  Sources
cost data
Screening
programme
administration
Staff, premises and
computer systems to
identify potential
screenees, issue
invitations, record results
and manage follow-up.
Also costs/fees
reimbursed to GPs and
other practitioners
involved in patient
selection and
management
Some administrative
costs are unrelated to
the size of the population
or the number selected
for screening (i.e. fixed
costs). Other costs are
proportionate to service
volumes
Variety of costs involved May be best estimated
by extrapolation from
existing population
screening services
Screening CT
examination
Direct cost of LDCT
examination
Although ideally cost of
travel and loss of
earnings should also be
considered, most of
those at risk are likely to
be close to or beyond
retirement age, so that
omitting these costs is
unlikely to be important
The use of dedicated
facilities (fixed or
mobile) for screening
may increase the use of
expensive facilities, thus
reducing the unit cost
National tariff charges
for outpatient CT
examination or
detailed costing of
special facilities
Confirmation and
diagnosis
Bronchoscopy, biopsy,
sputum cytology and/or
radiologically guided fine-
needle aspiration
Preferred practice varies
between centres
Use of each resource in
screened patients in
local area, or averaged
for UK needs to be
established
National tariff charges
for unit costs.
Sampling surveys
required for resource
use
Adverse events of
diagnostic
procedures
Additional hospital
episodes related to
diagnostic and invasive
procedures (e.g.
pneumothorax)
Adverse event rates
required for each
procedure used
National tariff charges
for unit costs. Analysis
of national hospital
episode statistics to
establish event rates
Follow-up of
suspicious and
inconclusive
screening results
Expected number of
further HRCTs per
patient, consistent with
follow-up detection
probabilities
National tariff charges
for outpatient HRCT
examination.
Detection probabilities
from study results or
observational studies
Curative surgery Average cost of surgical
episode to remove
affected tissue
The case-mix of
procedures carried out
can be expected to vary
with stage of disease as
well as the characteristics
of each patient. Routine
hospital statistics may not
record sufficient detail to
permit this analysis to be
carried out
Special surveys may be
necessary to relate
types of surgery to
disease stage. HRG
costing system costs
will need to be modified
to reflect the influence
of disease stage on
costs
National tariff charges
for unit costs, modified
for stage of disease.
Local/national surveys
of surgical case-mix
Follow-up
following surgery
Number and speciality of
outpatient follow-up
care, including planned
investigations
Outpatient visits and
investigations are not
routinely coded against
the original diagnosis and
surgical procedure
Patient surveys may be
necessary to establish
normal patterns of
follow-up resource use
Average national tariff
charges for speciality
visit costs and
investigations
continuedeffectiveness of a screening programme is directly
related to the prevalence of disease: if few cases are
found the cost per detection is much higher.
Next to efficacy, the question most in need of
further research is the possible harm arising from
screening. Current estimates suggest that a large
number of people screened will be falsely
identified by LDCT as probably or possibly
suffering from NSCLC. No attempt has yet been
made to assess the psychological consequences on
those affected (including their families), and the
evidence on the physical risks associated with
confirmatory testing is limited.
None of the published economic studies has
adequately considered the implications of
incidental findings from screening. The Irish
study52 suggests that as many as half of those
screened will have such findings, resulting in
considerable increases in costs and administrative
workload. Any UK-based RCTs of screening
should include comprehensive recording of all
incidental findings and follow-up investigations
and treatments.
Serious shortcomings are apparent in the evidence
available on healthcare resource use associated
with lung cancer and its treatment in the UK,
partly related to the lack of a high-quality cancer
register database similar to SEER in the USA. 
The failure of regional cancer registries to achieve
the completeness of coverage of all types of
relevant patient data suggests that there may be a
case for new investment and/or greater priority for
this function.
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TABLE 16 Elements of health-related cost required for evaluation of lung cancer screening (cont’d)
Cost element Description Comment Resource and  Sources
cost data
Supportive and
continuing care
A wide range of health
needs may occur
throughout a patient’s
remaining life. The
intensity of resource use
increases in the last
6–9 months of life,
although there are large
variations between
individuals
Health resource use in
late stage cancers is very
poorly researched in the
UK, although the amount
of care provided is often
much less than that
provided in other
developed countries
A consistent and
comprehensive UK cost
model of supportive
care needs to be
developed, which can
be calibrated for each
type of cancer from
patient surveys
Resource-use data are
scarce and largely
unreliable. 
By contrast, unit costs
can be obtained from
national sources
Care for incidental
findings
Evidence suggests that
there is a wide range of
potential conditions that
would incur healthcare
costs immediately, and in
some cases over long
periods
Each significant co-
morbidity will require a
separate economic
submodel to be
developed, and
assumptions must be
made about the extent
to which this healthcare
is additional expenditure
Detailed patient data
will be required from
studies to estimate
likely resource use.
Published sources may
furnish cost models for
some co-morbidities
Study data for
resource use.
National tariff charges
for inpatient and
outpatient care
Healthcare during
extended survival
A patient who is ‘cured’
following successful
surgery will gain extra
life-years, during which
time they suffer other
unrelated health
problems that incur costs
to the NHS. Estimating
these costs is necessary
for a budget impact
analysis, and (arguably)
may be included in a
cost-effectiveness analysis
It is not appropriate to
use a population average
resource-use profile,
since screenees are
generally selected for
their high risk of disease
A large, comprehensive
population database of
linked NHS resource
use is required. Patients
would be selected who
had curative surgery for
lung cancer, and their
subsequent resource
use analysed
An integrated
population database of
NHS resource use
HRG, health resource group.Although it has not been possible to develop a
meaningful economic model to assess the cost-
effectiveness of lung cancer screening, some
conclusions may be drawn about the optimal
organisation of a screening programme (assuming
that real health benefits have been demonstrated):
  Survival gains from a single screen would be
greatest at the age of 70 years.
  Each subsequent repeat screening yields
progressively smaller incremental gains.
  There is no basis for setting different screening
ages for men and women.
  Cost-effectiveness is greatest for a single screen
at the age of about 73 years.
  Cost-effectiveness is improved by targeting the
highest risk subpopulations.
So far, the cost-effectiveness of screening
compared with conventional practices (i.e.
symptomatic case finding and current treatment
patterns) has been discussed. However, it may be
argued that other options should also be
introduced into an economic assessment. First,
increased expenditure on preventive measures to
encourage smoking cessation, or to prevent young
people taking up smoking, may offer viable
alternatives, with long-term public health benefits
and potential economic gains. Second, lung cancer
treatment in UK is characterised by a generally
less aggressive approach to surgical intervention,
but also worse survival outcomes than many
European or North American countries.
Increasing services and funds to allow more lung
cancer patients to be actively managed can be
expected to yield important gains, which may also
be competitive in economic terms.
It appears that the evidence available on the
efficacy of CT screening is not yet strong enough
to permit a judgement to be made on whether it
should be implemented in the UK. The primary
requirement is for UK-based RCTs to be carried
out. However, it is also important that enabling
research be undertaken on the range of related
questions detailed in this section in the meantime.
Only then will researchers be adequately equipped
to undertake a robust assessment of alternative
approaches to reducing the burden of lung cancer. 
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he UK NSC criteria for evaluating screening
programmes were adapted from the WHO
criteria published in 1966. The criteria are
published by the NSC on their website.
This chapter applies the 22 criteria to lung cancer
screening and summarises the evidence presented
in the previous chapters. The authors’ view on the
extent to which the criteria are satisfied is
appended after each criterion.
The condition
1. The condition should be an important health
problem
By any definition of important, including
frequency of the disease, severity of the
consequences and economic burden, lung cancer
is as an important health problem in the UK.
Lung cancer heads the cancer league tables in the
UK for deaths, with around 34,000 people dying
each year. Prognosis is bleak and presentation as a
result of symptoms is generally late. Less than 10%
of people survive for more than 5 years after
diagnosis in the UK. Survival, while better in some
other countries and variable even within the UK,
does not surpass 20% at 5 years. At the time of
writing this report, NICE was in the process of
issuing guidance for the diagnosis and
management of lung cancer.1 This guidance was
issued in 2005. Although this may improve
survival to some extent, the best way of improving
survival is by surgical resection of tumours before
they have spread. Most lung cancers are detected
either as incidental findings on chest imaging or
because of symptoms. For most, symptoms reflect
the advance of the disease and 80% of lung cancer
in the UK presents with stage III or above. Less
than 10% of patients proceed to surgical resection.
Authors’ summary opinion: Fully satisfied.
2. The epidemiology and natural history of the
condition, including development from latent to
declared disease, should be adequately
understood and there should be a detectable risk
factor, disease marker, latent period or early
symptomatic stage
Screening studies have identified important gaps
in our understanding of lung cancer
epidemiology. The wide variation in prevalence
found, for example, when comparing ELCAP to
the MacRedmond study indicates that assumptions
of equivalence in disease detection rates cannot be
made.30,52 There is evidence that stage I and II
disease is associated with better survival with
surgery, but progresses to cause death if surgery is
not undertaken, but this comes solely from
unscreened populations. There are few data on
long-term follow-up of those with lung cancer
detected by screening. Some of those data from
screening programmes, particularly if non-
smokers are included, suggest that screening may
include the detection of some well-differentiated
tumours that grow more slowly, with a high
proportion of atypical adenomatous
hyperplasia/bronchioloalveolar adenoma. There is
evidence of debate among histopathologists about
the nature of this pathological finding, but it is
visible on CT as an NCN. One of the screening
studies has reported information about tumour
growth and indicates that some of the well-
differentiated small cancers detected by screening
grow very slowly.43 At present, there is insufficient
understanding to quantify the relationship
between NCNs, screening-detected lung cancer
and outcome.
Authors’ summary opinion: Not satisfied.
3. All the cost-effective primary prevention
interventions should have been implemented as
far as practicable
As smoking remains the predominant risk factor
for lung cancer, one could argue as to whether
everything practicable has been done by way of
primary prevention. Certainly smoking rates are
falling in most subgroups of the population.
However, further preventive measures remain to
be taken, including cessation of advertising,
measures to prevent the sale of cigarettes to
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Does screening for lung cancer using 
computed tomography meet the 
National Screening Committee criteria?underage people, the banning of smoking in
enclosed public places, better recording of
smoking in GP records, and systematic
intervention using nicotine replacement therapy
and other methods.
Regardless of successful implementation of
preventive action, smoking leaves with it a legacy
lasting for decades, and as Peto and colleagues
described, the increased risk of cancer associated
with smoking does not fall to close to background
level for decades after an individual ceases
smoking.7 As a result, despite the increasing effort
to promote smoking cessation, the benefits in terms
of lung cancer will not be seen for several decades.
Authors’ summary opinion: Partially satisfied.
4. If the carriers of a mutation are identified as a
result of screening the natural history of people
with this status should be understood, including
the psychological implications
Authors’ summary opinion: Not applicable.
The test
5. There should be a simple, safe, precise and
validated screening test
CT is a relatively simple investigation, at least from
the patients’ perspective. It involves the use of a
technology that has wide penetration throughout
the NHS. The safety of CT is good in terms of
acute adverse events. However, it does involve a
radiation dose that, while substantially reduced in
comparison to standard-dose CT, is higher than
that of a chest X-ray. The evidence of long-term
safety in terms of radiation-induced cancers is not
currently available. LDCT has been compared with
standard dose and has been demonstrated to lose
little in terms of precision for the identification of
NCN in the lung. In the setting of screening, there
is no gold standard for assessing validity other than
long-term follow-up and investigation of those with
abnormal screening CT examinations. LDCT is a
sensitive tool, identifying large numbers of
abnormalities in the lung. However, among the
studies reported here, the specificity was poor.
Many people had to undergo further investigation,
often involving further radiation exposure.
Authors’ summary opinion: Partially satisfied.
6. The distribution of test values in the target
population should be known and a suitable cut-off
level defined and agreed
The international studies that have been included
in this review demonstrate a variation in the
prevalence of positive CT examinations among the
different studies. This occurs even where similar
definitions of a positive CT have been used. The
differences may reflect differences between the
populations and as a result, make it difficult to
generalise from studies conducted outside the UK.
Although there is evidence that the risk of cancer
increases with increased NCN size, there is no
consensus about what constitutes a size that is too
small to cause significant risk of unresectable
cancer before the subsequent round of screening.
Of course, it is not the size per se that is of
importance, but rather the growth rate. In very
small nodules it should be noted that detecting an
important change in diameter can be challenging.
Authors’ summary opinion: Not satisfied for the
UK population.
7. The test should be acceptable to the
population
The studies reported here provide little if any
information about the acceptability of CT in the
setting of a screening programme, which may be
reduced by full explanation of the possible harms
of radiation.
Authors’ summary opinion: Not satisfied.
8. There should be an agreed policy on the
further diagnostic investigation of individuals with
a positive test result and on the choices available
to those individuals
In 2005, NICE issued on guidelines for the
diagnosis and management of lung cancer
presenting symptomatically or incidentally. These
guidelines were not constructed for the
management of screening-detected lung cancer
and modifications would be required if CT
screening were to be adopted in the future. From
the current evidence, there is no consensus on the
definition of a positive CT examination or how
individuals with a single small nodule should be
followed up in terms of either repeat imaging or
biopsy. Similarly, the subsequent surgical
management of screening-detected tumours has
not been agreed.
Authors’ summary opinion: Not satisfied.
9. If the test is for mutations the criteria used to
select the subset of mutations to be covered by
screening, if all possible mutations are not being
tested, should be clearly set out
Authors’ summary opinion: Not relevant.
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10. There should be an effective treatment or
intervention for patients identified through 
early detection, with evidence of early 
treatment leading to better outcomes than late
treatment
There is evidence to support the effectiveness of
surgical resection for stage I and II NSCLC. More
advanced stage disease is associated with poor
survival. For those not fit enough for surgery, there
is also evidence of better survival among early-
stage disease for those treated with radiotherapy.
However, their survival is substantially worse than
after surgical resection. What is absent currently is
RCT evidence that screening will achieve a
reduction in disease-specific mortality or total
mortality and as a result lead to extension of life
expectancy.
Authors’ summary opinion: Partially satisfied.
11. There should be agreed evidence-based
policies covering which individuals should be
offered treatment and the appropriate
treatment to be offered
NICE guidelines cover this, but it has not been
demonstrated that screening-detected lesions
should be managed in the same way as those
presenting as incidental findings or with symptoms.
As discussed above, there is no consensus on what
constitutes a positive screening test and how best to
follow up such individuals.
Authors’ summary opinion: Partially satisfied.
12. Clinical management of the condition and
patient outcomes should be optimised in all
healthcare providers prior to participation in a
screening programme
Variation in survival from lung cancer is seen when
comparing lung cancer survival both within the
UK and to other European countries that do not
screen. Evidence from the ‘best supportive care’
arms of studies in the UK is comparable to
Europe, so does not support the notion that the
disease is more aggressive or diagnosed later in
the UK. The rate of surgical intervention varies
widely both within the UK and compared with
other European countries. Similarly, variations in
the use of other treatment options for lung cancer
can be seen. At the time of writing the report,
NICE guidelines that aimed to improve this
situation were in the process of being delivered.
These were issued in 2005.1
Authors’ summary opinion: Not satisfied.
The screening programme
13. There should be evidence from high-quality
randomised controlled trials that the screening
programme is effective in reducing mortality or
morbidity
There is evidence from RCTs to date.
Authors’ summary opinion: Not satisfied.
14. There should be evidence that the complete
screening programme (test, diagnostic
procedures, treatment/intervention) is clinically,
socially and ethically acceptable to health
professionals and the public
Participation and recruitment into screening
studies is reported by most authors to be good.
However, none of the studies reviewed 
presented data about uptake of participation into
the study or reasons for refusal to participate.
Excluding Swensen and Sone, the other studies
that had run several years of follow-up all
reported poor compliance either with timing 
(e.g. attending on time for annual review) or 
with subsequent participation. In the only 
study115 that had run screening for up to 5 years,
participation was extremely poor. No reasons for
poor compliance were presented in the reports.
None of the reports included any measures of
quality of life or patient perceptions associated
with the screening programmes. None reported
any acceptability data for participating 
physicians.
Authors’ summary opinion: Not satisfied.
15. The benefit from the screening programme
should outweigh the physical and psychological
harm (caused by the test, diagnostic procedures
and treatment)
To date, the screening studies cannot provide 
an answer to this. Very little information about
harm has been published. None of the studies
identified has yet published any information
about the impact on quality of life from 
screening. A large number of screened people 
will have a positive screening test and require
some sort of further investigation. Algorithms to
reduce the inappropriate biopsy and surgical
resection of benign lesions minimised the 
number of people undergoing the most high-risk
procedures. The studies to date do not report 
well the adverse events from investigation of a
positive screening CT or management of lung
cancer.
Authors’ summary opinion: Not satisfied.
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programme (including testing, diagnosis and
treatment, administration, training and quality
assurance) should be economically balanced in
relation to expenditure on medical care as a
whole (i.e. value for money)
In view of the lack of evidence of effectiveness to
date, it is not possible to estimate the economic
impact of a screening programme for lung cancer
at present.
Authors’ summary opinion: Not satisfied.
17. There should be a plan for managing and
monitoring the screening programme and an
agreed set of quality assurance standards
In the absence of evidence of clinical or cost-
effectiveness for CT screening for lung cancer, this
criterion is not applicable at this time.
Authors’ summary opinion: Not applicable.
18. Adequate staffing and facilities for testing,
diagnosis, treatment and programme
management should be available prior to the
commencement of the screening programme
Although CT is a widely available technology, the
staff and facilities are already under heavy
demand within the service. Additional CT systems
and staff are likely to be required if a screening
programme is to be established in the UK.
Authors’ summary opinion: Not satisfied.
19. All other options for managing the condition
should have been considered (e.g. improving
treatment, providing other services), to ensure 
that no more cost-effective intervention could be
introduced or current interventions increased
within the resources available
There is evidence of regional variation in the
survival from lung cancer, and the survival data
from the UK are poorer than those from other
European countries. Although there are difficulties
in comparing the data between countries, there is
evidence to support the fact that there is room for
improvement in the management of lung cancer
in the UK both surgically and with chemotherapy.
The NICE 2005 guidelines address this.
Nonetheless, maximising all other management
options is not anticipated to provide
improvements in survival, because chemotherapy
and radiotherapy seldom effect cure.1,4,116
Authors’ summary opinion: Partially satisfied.
20. Evidence-based information, explaining the
consequences of testing, investigation and
treatment, should be made available to potential
participants to assist them in making an informed
choice
In the absence of evidence of clinical or cost-
effectiveness for CT screening for lung cancer, this
criterion is not applicable at this time.
Authors’ summary opinion: Not applicable.
21. Public pressure for widening the eligibility
criteria for reducing the screening interval, and
for increasing the sensitivity of the testing
process, should be anticipated. Decisions about
these parameters should be scientifically
justifiable to the public
The evidence for ideal screening intervals, cost
and clinical effectiveness, and eligibility criteria
cannot be acquired from the existing evidence
base. Long-term follow up from the current
screening programmes will provide information
about tumour doubling times and inform the
choice of eligibility criteria by providing a better
understanding of the risk of cancer versus the risk
of investigation in the population. International
data may not be generalisable to the UK, because
of the variation in risk of both lung cancer and
positive screening CT.
Authors’ summary opinion: Not applicable.
22. If screening is for a mutation the programme
should be acceptable to people identified as
carriers and to other family members
Authors’ summary opinion: Not relevant.
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From the review of clinical effectiveness, it can be
concluded that screening for lung cancer with CT
is technically feasible and identifies more people
with stage I cancer, compared with not screening.
At present there is, however, no evidence about the
impact of screening with CT on mortality.
Published economic analyses are therefore based
on the assumption that detecting more stage I
disease will translate into both a survival advantage
and improved mortality. Although this assumption
may be attractive, it is fraught with problems,
particularly for a condition that reaches a peak
incidence among the over 70-year-olds and is
associated with heavy and prolonged smoking. In
addition, there is currently no consensus on what
definition should be used for a positive screening
test or how best to follow up those with positive
screening tests. Finally, certain groups are at an
increased risk of lung cancer based on age and
exposure to cigarette smoke or as a result of
occupational exposures, current or past. To date,
there is insufficient evidence to support the
recommendation of screening for lung cancer in
any of these ‘high-risk’ groups. However, they
should be considered in the designing of any
future screening studies, when gathering
epidemiological data about lung cancer and in the
economic evaluation of screening should future
studies conclude that there is an improvement in
mortality as a result of CT screening.
In considering the economic argument for CT
screening for lung cancer, this study has
systematically considered the elements that would be
fundamental to any economic analysis. In doing so,
the conclusion was reached that it is not currently
possible to produce a meaningful economic analysis.
The lack of evidence of clinical effectiveness is
clearly fundamental but, in addition, uncertainty
around the understanding of the natural history of
screening-detected NCN and lung cancer, and the
poorly understood risk of harm associated with high
proportions of false-positive screening results are
among the problems identified.
Occupational at-risk groups
As noted previously, the increased risk of NSCLC
lung cancer associated with certain occupations
and exposures, particularly asbestos, may warrant
consideration of the feasibility of a screening
programme for workers or ex-workers. At present,
no RCTs have been conducted to assess
effectiveness of screening in such occupational
groups. As the lead time for development of lung
cancer in asbestos- and silica-exposed workers is
long, screening should focus on workers exposed
in the past. A case for screening would, therefore,
have to be made on an occupation-by-occupation
basis with evidence of the feasibility of running an
effective screening programme in that specific
population. Given the distribution of exposure to
substances such as asbestos, with highest exposure
in the UK among workers in shipbuilding areas
such as Glasgow, Newcastle and Portsmouth, it
may be feasible to use employee work records or
other means (such as local support groups and
trade unions) to identify at-risk individuals for
screening in these areas, although appropriate
approaches would depend on local circumstances.
The logistics of identifying people who were 
at risk in the past would have to be investigated.
The HSE would be an important collaborator 
and source of information under these
circumstances.
Specific weakness of the 
evidence base
To date, most of the clinical effectiveness data
have come from clinical studies with no
comparator group. While this design will help 
our understanding of issues of feasibility, 
protocols and to an extent the natural history of
the lesions detected, they do not answer the
fundamental question: does screening reduce
mortality? That cannot be answered without
control groups.
All the current studies are of relatively short
duration when considering the long-term survival
of patients with lung cancer. The studies have also
been restricted in terms of number of participants,
and hence have limitations in terms of power
when considering population screening for a
condition that has a prevalence of around 2% in
the participants screened.
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DiscussionIn terms of developing an economic case for
screening, there are problems in generalisability of
results to the UK from other countries, in terms of
both the number of screen-positive participants
and false-positive rates. The detection of
incidental disease other than lung cancer also
varied substantially between studies. The lack of
robust and detailed UK data on stage from lung
cancer registries has been identified in previous
lung cancer-related technology appraisal reports
and remains an issue when trying to model
survival. There is also a lack of data about the
current costs and utilisation of lung cancer
services, which makes meaningful extrapolation of
costs difficult.
Conclusions for NHS and NHS
policy
In the authors’ view, CT screening for lung cancer
does not currently meet the accepted NSC criteria.
Table 17 summarises the current evidence, but
most criteria are not satisfied, with no RCTs, no
evidence of clinical effectiveness against mortality
and no evidence of cost-effectiveness. Even if all
the other criteria were satisfied, a screening
programme would have to pass the cost per QALY
hurdle; the threshold range generally followed by
NICE is £20,000–30,000 per QALY, although it is
far from certain that the NHS can afford as much
as that.
CT studies planned or in progress
Table 18 briefly outlines the CT screening studies
for lung cancer that were identified with the
search strategy as being underway at present.
Some of these studies will eventually provide
information relating to the effect of screening on
mortality. Others may add to our understanding of
the natural history of NCNs detected by screening,
about the protocols used for screening and about
which populations will benefit most from
screening. Only the LUCAS trial is anticipated to
occur in the UK, but it currently remains
unfunded. Although the US trial117 has progressed
through the pilot stage, it will not provide answers
Discussion
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TABLE 17 Summary of NSC criteria
Criterion Authors’ summary opinion Comments
Disease
1 Fully satisfied Despite other preventive initiatives being feasible, they would 
2 Not satisfied not affect the population proposed for screening for several 
3 Partially satisfied decades
4N A
Test
5 Partially satisfied
6 Not satisfied
7 Not satisfied
8 Not satisfied
9N A
Treatment
10 Partially satisfied
11 Partially satisfied
12 Not satisfied
Programme
13 Not satisfied Some of the later criteria are less relevant until screening has 
14 Not satisfied been approved in principle
15 Not satisfied
16 Not satisfied
17 Not applicable
18 Not satisfied
19 Partially satisfied
20 Not yet applicable
21 Not satisfied
22 NAHealth Technology Assessment 2006; Vol. 10: No. 3
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about the effect of screening on lung cancer
mortality for approximately 10 years. In the
meantime, addressing the other research needs
above would facilitate a rapid response to studies
if they did demonstrate effectiveness of screening. 
Research needs
In terms of what information is needed to make
such a decision, the following research needs were
identified.
  RCT evidence is needed that CT screening
reduces mortality, either with whole-population
screening or for particular subgroups.
  UK data about the rate of positive screening CT
and detected lung cancers could be obtained
from an RCT or a cohort study. Even relatively
small-scale studies would provide valuable
information when trying to assess the
generalisability of RCT data currently being
conducted elsewhere.
  There is a need to understand better the
natural history and epidemiology of screening-
detected lung cancers, particularly small, well-
differentiated adenocarcinomas. This could be
met, in part, by lung cancer screening RCT or
cohort studies, but a review of existing
published epidemiological and pathological
data along with primary analysis of UK lung
cancer epidemiology would valuably inform
current understanding.
  Information about the quality of life impact of
CT screening, acceptability of screening, and
uptake and retention rates in the UK would be
valuable in any future assessment of the cost-
effectiveness of screening in the UK.
  Increased routine collection is needed of UK
health service data regarding resource
availability, utilisation and safety data for lung
cancer management and services.
  Research is needed into the feasibility and
methods of tracking those who were previously
occupationally exposed to lung carcinogens.
The authors believe that screening for lung cancer
using CT cannot be recommended based on
current evidence and, while more definitive
evidence of effectiveness is being sought, priority
should be given to reducing exposure to risk
factors for lung cancer, in particular smoking.
TABLE 18 Studies of CT screening planned or in progress
Trial Country Methods Timing and current status
DEPISCAN118 France RCT of CT vs CXR. Pilot of 1000 smokers. Unclear: protocol published in
Full trial 20,000. Outcomes include  2002
economics and QoL
LUCAS119 UK Pilot 2000 smokers. Full trial 40,000–60,000 Currently  unfunded
smokers RCT of CT vs usual care. 
Outcomes include QoL and economics
ACRIN and NCI  USA RCT of CT vs CXR. 50,000 smokers. Recruiting in 2003 with 
Lung Screening Trial117 Pilot study known as LSS 27 anticipated end in 2009
Paci120 Italy RCT of CT vs usual care. 1500 smokers.  Apparently 2002–2007, 
Using ELCAP protocol for collaboration.  but financial support was still 
?10,000 participants in full trial being confirmed
Denmark120 Denmark RCT of CT vs usual care. Full trial of  Unknown
10,000 current smokers. Outcomes include 
QoL and economics
Holland120 Holland RCT of CT vs usual care. Full trial of  Unknown
24,000 smokers. Outcomes include QoL 
and economics
Norway120 Norway RCT of CT vs usual care. Full trial of  Unknown
24,000 smokers
ACRIN, American College of Radiology Network; NCI, National Cancer Institute.Health Technology Assessment 2006; Vol. 10: No. 3
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Appendix 1
Summary of occupational associated risk
of lung cancerAppendix 1
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Appendix 2
Literature search results
Identified on searching
n = 1041
Relevant titles and keywords
n = 262
Full papers for appraisal
(after review of abstract)
n = 86
Papers for economics 
review
n = 23
Papers for effectiveness 
review
n = 38 + 25 reviews
Included in review of 
economics
n = 6 
Included in review of 
effectiveness
n = 29 (12 trials) + 3 
systematic reviews
Excluded
n = 779
Excluded
n = 176
Flowchart of identification and inclusion of studies: systematic reviews, RCTs and other trials. Reviews were included if English language
only. Health Technology Assessment 2006; Vol. 10: No. 3
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T
he following search terms were used to
identify relevant articles:
MEDLINE
1994–2005
1. exp Lung Neoplasms/all subheadings
2. exp Carcinoma, Non-Small-Cell Lung/
3. exp Carcinoma, Small Cell/
4. lung cancer$
5. lung neoplasm$
6. small cell carcinoma
7. lung adj1 carcinoma
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Mass Screening/all subheadings
10. screen$
11. exp Tomography, X-Ray Computed/all
subheadings
12. CT screening OR CT scan$
13. 9 or 10 or 11 or 12
14. 8 and 13
Last searched 1 February 2005
Embase
1994–2005
1. exp Computer Assisted Tomography/ or exp
Spiral Computer Assisted Tomography/all
subheadings
2. exp MASS SCREENING/ or exp 
SCREENING/
3. CT scanning
4. CT screening
5. computer assisted tomography
6. 1 or 2 or 3 or 4 or 5
7. exp cancer screening/
8. exp Lung Cancer/all subheadings
9. exp Lung Tumor/all subheadings
10. exp Lung Nodule/all subheadings
11. exp lung carcinoma/ or exp lung sarcoma/
12. lung cancer
13. lung neoplasm$
14. lung tumour$
15. lung tumor$
16. lung carcinoma$
17. lung nodule$
18. lung sarcoma$
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or
16 or 17 or 18
20. 6 and 19
21. lung$
22. 7 and 21
23. 20 or 22
Last searched 1 February 2005
The Cochrane Library
Issue 3 2004 (including CRD databases DARE,
NHS EED and HTA)
Searched on lung neoplasms (MESH exp all trees)
or lung cancer or lung neoplasm* AND
Tomography, X-ray computed (MESH exp all
trees) or CT screening or CT scanning.
Bandolier
Searched on lung cancer, CT screening, cancer.
American Society of Clinical
Oncology (ASCO) meeting
abstracts
Searched on lung cancer screening, CT screening
and lung, computed tomography and screening,
CT scanning, whole body, full body.
Science Citation Index and Social
Science Citation Index
1994–2004
ISI Proceedings
Searched lung cancer OR lung neoplasm* AND
CT Scan* OR CT Screen* OR computer assisted
tomography
HMIC
Searched exp lung cancer AND screening OR exp
mass screening OR screening policy OR screening
Appendix 3
Search strategyAppendix 3
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services. Also searched cancer screening OR
screening programmes.
ReFeR (Research Register)
Searched lung cancer, lung AND screening, cancer
AND screening, computed tomography, CT
scanning, CT screening.
National Research Register
Searched exp lung neoplasms (MESH) AND mass
screening (MESH), lung cancer AND mass
screening, cancer AND CT screen*.Health Technology Assessment 2006; Vol. 10: No. 3
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Appendix 4
Data extraction summaries
Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Gohagan, 2004, USA28
Design: RCT vs CXR
Funding: NCI (not
commercial)
Quality
Randomisation? Adequate
Allocation concealment? Not adequately described
Similar at baseline? Adequate
Eligibility criteria specified? Adequate
Withdrawals described? Only baseline screen reported
Outcome valid? Adequate
Follow-up adequate? Pilot study
Comments
NNS to detect 1 lung cancer = 53
NNS to detect 1 resectable lung cancer = 99
1.5% of screening CT examinations led to biopsy for benign disease
Selection: population
Age: 55–74 y
Smoking: 30 pack-year
(quit <10 y)
High risk: yes
Definition: NCN
Size: > 3 mm (any for
spiculated NCN)
No. of NCN: 1–6
HRCT: not specified
Follow-up: CT controls
(not specified)
Biopsy: indicated where
necessary
Screened:
CT: 1586
CXR: 1550
Positive scan:
CT: 20.5%
CXR: 9.8%
Lung cancer:
CT: 30 (1.9%)
CXR: 7 (0.5%
Resected: 
No data
Diagnosis AEs:
CT: 6
CXR: 6
5-y survival:
no data
QoL:
no data
AE, adverse event.Appendix 4
80
Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Garg, 2002, USA27
Design: RCT vs no
screening 
Funding: independent
Quality
Number of cancers in the text does not match table data (table data used)
Randomisation? Not adequately described
Allocation concealment? Not adequately described
Similar at baseline? Adequate
Eligibility criteria specified? Adequate
Withdrawals described? Only baseline screen reported
Outcome valid? Adequate
Follow-up adequate? No; not for mortality
Comments
NNS to detect 1 lung cancer = 31
NNS to detect 1 resectable lung cancer = NR
Selection: population
(Veterans Affairs
medical centres)
Age: 50–80 y
Smoking: 30 pack-years
High risk: yes; atypical
sputum cytology+
COPD (n = 55)
Definition: NCN
Size: any
No. of NCN: 1–6
Follow-up: nodules
≤ 5 mm repeat HRCT
at 3, 6, 12, 24 months
6–10 mm individual
assessment
>10 mm: enhanced CT
then biopsy
Screened:
CT: 92
No screen: 98
Positive scan:
33%
Lung cancer:
CT: 3 (3.2%) 
No screen: NR
not reported
Resected:
NR
AEs:
no data
5-yr survival:
no data
QoL:
no dataHealth Technology Assessment 2006; Vol. 10: No. 3
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
ELCAP , 2001, USA30
Design: no comparator
group
Funding: NIH +
Eastman – Kodak
Corporation + General
Electric Corporation
Quality
Sample representative? Not described
Groups described? Adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Interim report 
Withdrawals described? Adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
Also identified 4 mediastinal/central tumours; not included in total by trialists
NNS to detect 1 lung cancer = 37 (baseline); 169 (incidence)
NNS to detect 1 resectable lung cancer = 37 (baseline); 197 (incidence)
0.2% of screenees offered biopsy for what was eventually confirmed as benign disease from baseline round
Selection: population
Age: median 60+ y
Smoking: 10 pack-years
High risk: asbestos
exposure in 14%
Definition: NCN or
ground glass
Size: any
No. of NCN: 1–6
All: HRCT immediately,
antibiotics then HRCT
at 1 month
Follow-up: ≤ 5m m
HRCT at 3, 6, 12,
24 months
Biopsy: >5mm
Screened: 
Baseline: 1000
Incidence: 1184
Positive scan:
Baseline: 23.3% 
Incidence: 3.4%
Lung cancer:
Baseline: 27 (2.7%)
Incidence: 7 (0.6%)
AEs:
no complications from
biopsy 
5-y survival:
no data
QoL:
no dataAppendix 4
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Kaneko, 2002, Japan37
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? Not adequate
Comparator group? None
Eligibility criteria described? adequate
Follow-up adequate? 5-year follow-up for some participants 
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
Also found 3 cancers from sputum cytology alone (CT negative)
NNS to detect 1 lung cancer =115 (baseline); 420 (incidence)
NNS to detect 1 resectable lung cancer =134 (baseline); 464 (incidence)
0.25% of screening CT examinations led to biopsy for benign disease
Selection: population
Age: 40+ y
Smoking: 20 pack-years
Definition: 
(a) inadequate image
(b) normal
(c) scar lesion caused
by previous
inflammatory
episode
(d) benign tumour or
an active
inflammatory
disease
(e) suspected lung
cancer
Size: any
No. of NCN: 1 or
more
Follow-up: if graded (d)
or (e) followed up with
HRCT
If still considered
possibly malignant then
biopsied
Screened: 
Baseline: 1611
Incidence: 7891
Positive scan:
Baseline: 11.5%
Incidence: 9.1%
Lung cancer: 
Baseline: 13 (0.8%)
Incidence: 19 (0.2%)
Resected:
Baseline: 12
Incidence: 17
5-y survival:
71%, with overall
higher survival rate for
those detected at
baseline screening
(76.2% vs 64.9%)
Lung cancer
mortality: no data
Surgical AEs:
no data
QoL: no dataHealth Technology Assessment 2006; Vol. 10: No. 3
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Diederich, 2004,
Germany40
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? Adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Interim report
Withdrawals described? Adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
Funding limitations resulted in changes to follow-up procedures during trial. Reported as number of lesions rather than
people, therefore data extraction complicated. Large numbers of patients lost to follow-up
NNS to detect 1 lung cancer = 48 (baseline); 578 (incidence)
NNS to detect 1 resectable lung cancer = 51 (baseline); 578 (incidence)
Selection: population
Age: 40+ y
Smoking: 20 pack-years
Definition: NCN
Size: any
No. of NCN: 1 or
more
Follow-up:
All: immediate thin-
section LDCT
<10 mm: follow-up
with HRCT at 3, 6, 12,
24 months
>10 mm: biopsy
immediately if
suspected malignant
(otherwise follow-up as
above)
If growth then contrast-
enhanced CT and/or
PET used
Screened: 
Baseline: 817 
Incidence: 1735 
Positive scan: 
Baseline: 43% 
Incidence: 5.1% 
Lung cancer:
Baseline: 17 (2.1%)
Incidence: 3 (0.2%)
Resected:
Baseline: 16 (100%)
Incidence: 3 (100%)
5-y survival:
no data
AEs:
no data 
QoL:
no dataAppendix 4
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Sone, 2001, Japan29
Design: no comparator
group
Funding: 
non-commercial
Quality
Sample representative? Not described
Groups described? Not adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Not adequate: 5-year survival only for people with tumours detected at baseline
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 249 (baseline); 755 (incidence)
NNS to detect 1 resectable lung cancer = 249 (baseline); 755 (incidence)
Selection: population
Age: 40+ y
Smoking: smokers and
non-smokers
High risk: dependent
on smoking status
Definition: 
(A) examination
unsatisfactory; 
(B) normal; (C) lung
abnormality of little
clinical importance;
(D) non-cancerous
lung lesion; (Ed) non-
cancerous but
suspicious lung lesion;
(E) suspicion of lung
cancer; (F) small lung
nodule (<3 mm in
diameter) Ed, E or F
seem to be considered
suspicious
Size: any
No. of NCN: any
Follow-up: HRCT for
Ed, E and F. If nodules
indeterminate then
follow-up CT at 3, 6,
12, 18, 30 months
Biopsy: indicated
‘where necessary’
Screened: 
Baseline: 5483 
Incidence: 8303
Positive scan:
Baseline: 5.1%
Incidence: 3.7%
Lung cancer:
Baseline: 22 (0.4%)
Incidence: 34 (0.4%)
Resected:
Baseline: 22
Incidence: 34
AEs:
no data
5-yr survival: 
no data
QoL:
no dataHealth Technology Assessment 2006; Vol. 10: No. 3
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Swenson, 2003, USA46
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? 2 year follow-up; not adequate for survival
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 58 (baseline); 324 (incidence)
Selection: population
Age: 50–85 y
Smoking: 20 pack-years
(quit <10 y)
Definition: NCN
Size: any
No. of NCN: 1 or
more
Follow-up:
<4 mm: HRCT within
6 months
4–8 mm: HRCT within
3 months
8–20 mm: HRCT ASAP
Immediate biopsy for
nodules >20 mm
Repeat scans for 2 y to
assess for growth
(frequency not
specified)
Biopsy: if >20 mm or is
indicated from HRCT
scan or if growth
Screened:
Baseline: 1520
Incidence: 2916
Positive scan: 
Baseline: 51% 
Incidence: 11.5%
Lung cancer: 
Baseline: 26 (1.7%)
Incidence: 9 (0.3%)
AEs:
7 benign lesions
biopsied
5-y survival:
no data
QoL:
no dataAppendix 4
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Pastorino, 2003, Italy50
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? Adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? 2-year report of 5-year project
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 94 (baseline); 91 (incidence)
NNS to detect 1 resectable lung cancer = 104 (baseline); 91 (incidence)
Selection: population
Age: 50–84 y
Smoking: 20 pack-years
High risk: yes
Definition: NCN
Size: >5 mm
No. of NCN: 1 or
more
Follow-up: >5 mm
follow-up with HRCT
within 1 month.
If >5 mm and density
>0 Hounsfield units on
HRCT then assessment
of contrast
enhancement.
Nodules ≥ 7 mm on
HRCT followed by PET
Biopsy: nodules
biopsied if positive
enhancement (>30
Hounsfield units) or
positive PET scan or
NCN ≥ 20 mm unless
unequivocally benign at
HRCT. Also biopsied if
>7 mm in contrast
enhancement on CT
but negative PET or
>7 mm with no
enhancement but
positive PET
Screened: 
Baseline: 1035
Incidence: 996
Positive scan:
Baseline (5.9%)
Incidence (3.4%)
Lung cancer:
Baseline: 11 (1.1%)
Incidence: 11 (1.1%)
Resected: 
Baseline: 10 
Incidence: 11
5-y survival:
no data
AEs: 6 resections for
benign disease
QoL: 
no dataHealth Technology Assessment 2006; Vol. 10: No. 3
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Nawa, 2002, Japan51
Design: no comparator
group
Funding: not stated
Quality
Sample representative? Not described
Groups described? Not adequate
Comparator group? None
Eligibility criteria described? Not adequate
Follow-up adequate? Interim report 
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 221 (baseline); 1392 (incidence)
Selection: employee
health insurance group
Age: 50+ y
Smoking: some current
and past smokers
High risk: some
(current and past
smokers)
Definition: NCN
Size: >7 mm
No. of NCN: 1–6
Follow-up: NCNs
>7 mm: detailed CT at
1 month. NCNs
8–10 mm: examined
with detailed CT scans
at 3, 6 months
Biopsy: growth or
NCNs ≥ 11 mm
Screened:
Baseline: 7956
Incidence: 5568
Positive scan:
Baseline: (6.8%)
Incidence: (2.7%)
Lung cancer:
Baseline: 36 (0.45%)
Incidence: 4 (0.07%)
Resected:
no data
AEs: 18 underwent
biopsy for benign
disease
5-y survival:
no data
QoL:
no dataAppendix 4
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
MacRedmond, 2004,
Ireland52
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? Adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Not for 5-year survival 
Withdrawals described? Only baseline screen reported
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 225 (baseline)
NNS to detect 1 resectable lung cancer = 449 (baseline)
Selection: population
Age: 50+ y
Smoking: 
10 pack-years, still
smoking at 45 y
High risk: yes
Definition: NCN
Size: any
No. of NCN: 1–6
Follow-up: positive
screen follow-up with
HRCT for nodules
≤ 5 mm at 6, 12,
24 months. 6–10 mm:
individual assessment
indicating further
follow-up (as for
≤ 5 mm) or biopsy
Biopsy: >10 mm
Screened: 
Baseline: 449 
Positive scan:
Baseline: 24% 
Lung cancer:
Baseline: 2 (0.4%)
Resected:
Baseline: 1 (100%)
AEs: 
benign hamartoma
removed
5-y survival: 
no data
QoL: 
no dataHealth Technology Assessment 2006; Vol. 10: No. 3
89
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Huuskonen, 2002,
Finland53
Design: no comparator
group
Funding: non-
commercial
Quality
Sample representative? Not described
Groups described? Adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Adequate (lung cancer patients all died, screen negatives followed for 3 years using cancer registry;
no additional lung cancers reported)
Withdrawals described? Only baseline screen reported
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 120 (baseline)
NNS to detect 1 resectable lung cancer = 602 (baseline)
Selection: population
Age: mean age 63
(38–81) y
Smoking: average
24 pack-years
High risk: yes; all with
occupational exposure
to asbestos
Definition: NCN
Size: > 5mm
No. of NCN: 1 or
more
Follow-up: poorly
reported.
Biopsy: ‘when
malignancy could not be
ruled out’; otherwise
follow with CT
Screened: 602
Positive scan:
18.4%
Lung cancer:
5 (0.8%)
Resected: 1
5-y survival:
all died within
21 months of
prognosis
AEs:
no complications from
biopsy 
QoL:
no dataAppendix 4
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Reference and design Study population  Screening criteria Diagnostic criteria Outcome
and selection
Miller, 2004, USA55
Design: cohort
Funding: not reported
Quality
Reported as a brief letter with very little detail
Sample representative? Not described
Groups described? Not adequate
Comparator group? None
Eligibility criteria described? Adequate
Follow-up adequate? Not for 5-year survival
Withdrawals described? Not adequate
Outcome valid? Assessment of lung cancer valid. Not designed to assess mortality
Comments
NNS to detect 1 lung cancer = 163 (baseline)
Selection: nuclear fuel
workers
Age: ≥ 45 y
Smoking: 34% non-
smokers; 15% current
smokers; 51% ex-
smokers (71% of
whom quit ≥ 15 y
earlier)
High risk: yes;
occupational exposure
Definition: not
specified.
Indeterminate or
suspicious scans
deemed positive
Size: not specified
No. of NCN: not
specified
Follow-up: positive scan
rescanned with HRCT.
If scan remained
indeterminate then
rescans performed at 
3-, 6-, 12-, 18-month
intervals
Biopsy: not specified
Screened: 3598
Positive scan: 32% 
Lung cancer: 
Baseline: 22 (0.64%)
Incidence: 1 (%?) 
No other details of
incidence screening
reported
AEs:
no complications from
biopsy 
5-y survival: 
no data
QoL: 
no dataHealth Technology Assessment 2006; Vol. 10: No. 3
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